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The purpose of this quality improvement project was to determine if screening 
primary care patients with psoriasis will improve early detection of celiac disease (CD), 
rheumatoid arthritis, and Crohn’s disease (CrD).		The aim of this project is to assess the 
utility of early screening in patients with psoriasis in order to facilitate earlier diagnosis 
of CD, RA and CrD, which would consequently initiate earlier treatment and improve 
long-term patient outcomes.  Genetic and population-based studies suggest that 
individuals with psoriasis have a greater risk of also having CrD, CD or RA, than do 
individuals without psoriasis.  The literature also suggests that health care providers 
would be prudent to evaluate psoriatic patients in a prospective manner for these AI 
disorders in order to improve the patient’s long-term health outcomes. 
Based on the literature, the DNP project investigator developed a non-
psychometric patient questionnaire to capture data including the signs and symptoms of 
CD, CrD and RA and three referral algorithms (one each per CD, CrD and RA).  Over 
two weeks at a Northern Virginia dermatology clinic, the patient questionnaire was 




Findings indicated 100% provider compliance documentation for all 34 patients 
noting that the patient a) had been screened, and b) if referral was or was not indicated.  
Frequency data indicated that the most reported symptom was a history of vitamin D 
deficiency (38.24%).  Thirty percent of psoriatic patients reported having a first-degree 
relative with celiac disease, Crohn’s disease or rheumatoid arthritis.  The most frequently 
reported symptoms were for rheumatoid arthritis: daily joint or muscle pain > 6 weeks 
(29.41%), daily tender or swollen joints > 6 weeks (23.53%), and weakness or fatigue > 6 
weeks (23.53%).  The most reported GI symptom was abdominal distention and/or 
bloating after eating (14.71%).  The least reported symptoms, at 2.94% each, were 
abdominal pain after eating, painful bowel movements, and running a fever in the past 4 
weeks. This quality improvement project highlights the need to evaluate adult patients 
with psoriasis for polyautoimmunity and familial autoimmunity and is consistent with the 
literature that recommends screening for these polyimmune relationships.  
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Autoimmune (AI) diseases refer to a collection of diseases where the immune 
system mistakenly directs the body to attack its own healthy organs, tissues, and blood, 
rather than the foreign organisms the immune response was designed to combat.		 The 
result is impaired function of the targeted organ or system.  The National Institute of 
Health ([NIH], 2005) has identified more than 80 clinically distinct autoimmune 
disorders, while the American Autoimmune Related Disease Association ([AARDA], 
2011) recognizes greater than 100 known autoimmune diseases.  Psoriasis, a chronic, 
inflammatory skin disease, is known to be the most prevalent AI disease in humans 
(Raychaudhuri, 2014), affecting approximately 2-5% of the world population and as 
many as 7.5 million Americans (NIH, 2005).    
Psoriasis belongs to a subset of AI diseases classified as Immune-Mediated 
Inflammatory Diseases (IMIDs) (Rahman, Inman, El-Gabalawy & Krause, 2010).  The 
concept of IMIDs describes a group of seemingly unrelated clinical disorders that share 
common inflammatory pathways.  While all IMIDs are AI diseases, the reverse is not 
also true; all AI diseases are not IMIDs.  Central to the disease process in IMIDs is the 
imbalance and dysregulation of cytokine production (Rahman et al., 2010; Kuek, 
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Hazleton & Astor, 2007; Williams & Meyers, 2002).  Cytokines play a pivotal 
role in normal immune function.  When these molecules are inappropriately expressed, 
chronic inflammatory conditions arise.  Celiac Disease (CD), Rheumatoid Arthritis (RA) 
and Crohn’s Disease (CrD) also belong to this subset.   
Another relatively new concept in the autoimmune field is polyautoimmunity, 
which is defined as the coexistence of more than one AI disease, or IMID, in a single 
individual (Rojas-Villarraga, Amaya-Amaya, Rodriguez-Rodriguez, Mantilla, & Anaya, 
2012; Anaya, 2014).  Research suggests that individuals with one autoimmune disease 
typically will develop an additional one or more separate, and distinct, autoimmune 
diseases over the course of their lifetime (Cooper, Bynum & Somers, 2009).  Recent 
population-based studies, as well as studies that have identified common genes associated 
with multiple AI disorders, lend credibility to this idea that polyautoimmunity is not 
random, and that there is a true association between different AI disorders.  Specifically, 
studies suggest that individuals with psoriasis have a greater risk of also having another 
IMID, such as CrD, CD or RA, than do individuals without psoriasis (Augustin, Reich, 
Glaeske, Schaeffer & Radtke, 2010; Bhatia, Millsop, Debbanch, Koo, Linos & Liao, 
2014; Birkenfeld, Dreiher, Weitzman & Cohen, 2009; Cohen, Dreiher & Birkenfeld, 
2009; Damasiewicz-Bodzek & Wielkoszynski, 2008; Einarsdottir et al., 2009; Li, Han, 
Chan & Qureshi, 2013; Makredes, Robinson, Bala & Kimball, 2009; Qui, Z., Zhang, X. 
Qui, Zhou & Li, 2013; Radtke et al., 2015; Tsai et al., 2011; Tsoi et al., 2013; Wolf et al., 
2008; Wu, Nugyen, Poon & Herrington, 2012). 
Although these advances in research have fostered a greater understanding of 
autoimmunity in the health care community, AI diseases continue to be one of the most 
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clinically difficult to recognize categories of disease.  According to the AARDA (2011), 
it can take patients an average of five years and four health care professionals to obtain a 
correct diagnosis.  Diagnostically, IMIDs remain a challenge for both patients and health 
care providers.   The initial presentation of symptoms may be vague and confused with 
other disease processes (AARDA, 2011).  Additionally, health care professional 
education provides minimal training about AI diseases, contributing to a poor 
understanding of autoimmunity among primary health care providers.  As a result, despite 
the proven genetic component in AI disease, health care practitioners do not typically 
inquire whether patients have a personal or family history of autoimmune diseases, or 
screen for additional autoimmune diseases in the autoimmune patient.  Lastly, there are 
very few standardized tests for many of the 80-100 AI diseases (AARDA, 2011).   These 
gaps of knowledge represent lost opportunity for the patient whose disease process 
remains unchecked and whose associated AI co-morbidities also go unaddressed.   
Despite the differences in heterogenic expression and clinical characteristics 
among the IMIDs’ psoriasis, CrD, CD and RA, the shared genetic and pathophysiologic 
mechanisms suggest a common origin, and as health care providers, it is imperative to 
capitalize upon this information.  The potential links between these diseases a) must not 
be ignored and b) must be further studied.   The purpose of this project is to conduct a 
substantive review of the literature and conduct screening of primary care patients with 
psoriasis to determine early detection of celiac disease, rheumatoid arthritis, and Crohn’s 
disease. 
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1.2 Scope of problem 
Autoimmune diseases. Autoimmune diseases, to include the immune-mediated 
inflammatory diseases, can affect virtually every site in the body, including the nervous, 
gastrointestinal, and endocrine systems, as well as skin and other connective tissue, eyes, 
blood and blood vessels.  These diseases are chronic conditions, for which there currently 
is no cure.   Autoimmune and immune-mediated inflammatory diseases follow a 
progressive path, with more end-organ destruction over the passage of time.  Symptoms 
tend to increase in severity as the disease progresses and as more tissue destruction 
occurs (San Jose Functional Medicine, 2012).  While many of these diseases have low 
prevalence as a single occurring health disease, collectively autoimmune diseases are the 
third most common category of disease in the United States after cancer and heart disease 
(NIH, 2005) affecting approximately 5-8% of the population or approximately 23.5 
million Americans.  For reasons unknown, their prevalence is rising, while paradoxically, 
they continue to remain under detected and under diagnosed (NIH, 2005; AARDA, 
2011).  
 Early diagnosis and treatment is key to staving off disease progression and 
improving patient outcomes.  However, it is also recognized that there is often a delay in 
diagnosis due to the fact that symptoms are often vague, misdiagnosed, and treated 
symptomatically.  The delay in diagnosis and treatment can unfortunately, lead to poorer 
clinical outcomes associated with accrued joint and organ damage. 
Researchers have been uncertain exactly what triggers an autoimmune response, 
but certain modifiable and non-modifiable factors that play a role in autoimmunity have 
been identified (AARDA, 2011; NIH, 2005).  Modifiable factors include an individual’s 
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genetic predisposition toward autoimmunity, while non-modifiable factors could be 
anything from viruses, bacteria, medications, pollutants, or hormones.  Autoimmune 
disorders present disproportionately, and predominately, in the female population, are the 
second highest cause of chronic disease (AARDA, 2011) and have been among the top 
ten leading causes of death for women in every age group up to 64 years of age (NIH, 
2005). 
Incidence and Prevalence.	  In the United States alone, these AI diseases affect 
approximately 5-8% of the population, or 14 to 23.5 million individuals (NIH, 2005).   
However, the current data about the prevalence of these diseases in the United States is 
misleading, since most autoimmune disorders are asymptomatic for years before a 
clinical pattern emerges.  Due to the silent nature of AI disease onset, one can logically 
extrapolate that the true numbers of individuals with autoimmune disorders is actually 
much higher than the statistics suggest.   Many patients with AI disorders remain 
undiagnosed and therefore, have simply not been included in the current numbers.  
Furthermore, according to the AARDA (2011), the prevalence of autoimmune disorders 
as reported by the National Institute of Health, 14 to 23.5 million individuals was quite 
deflated, since the statistic only accounted for 24 of the 80 recognized autoimmune 
diseases.  The AARDA (2011) estimates that the actual number of individuals that have 
autoimmune diseases is closer to 50 million.   
There is no doubt that the actual burden of these autoimmune diseases to society, 
and to individuals, is enormous.  Individually, these chronic and progressively 
deteriorating disorders have caused emotional and financial challenges associated with 
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lost productivity; decreased quality of life; co-morbid mental illnesses, particularly 
depression and anxiety; and the disruption of social and family structures (NIH, 2002).    
Costs.  Quantifying the societal cost burden of AI disease has proven to be a 
problematic task, as well.  AARDA (2011) and NIH (2002) both agree that the lack of 
epidemiological data on autoimmune disorders has made it difficult to calculate the full 
direct and indirect cost to the overall health care system due to autoimmune disease.  In 
2001, the National Institutes of Allergy and Infectious Diseases (NIAID) Director, Dr. 
Anthony Fauci estimated that annual autoimmune disease treatment costs were greater 
than $100 billion.  Again, this number most likely underrepresents the true cost burden of 
disease, as the annual costs of only seven autoimmune diseases (Crohn's disease, 
ulcerative colitis, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis and 
scleroderma), have been estimated to total from $51.8-$70.6 billion annually (AARDA, 
2011). 
Psoriasis.  In 2010, the Centers for Disease Control and Prevention (CDC) 
initiated a public health agenda for psoriasis in order to better characterize the burden of 
psoriasis on the United States population, and to expand the existing knowledge base.  
Examining data from the 2003-2006 and 2009-2010 National Health and Nutrition 
Examination Surveys, key indicators such as prevalence, severity, disparities, health-
related quality of life and selected comorbidities were analyzed.  The initiative found that 
the overall prevalence of psoriasis in the United States is approximately 3.1%, affecting 
6.7 million adults aged 20 and greater (Hemlock, Lee-Han, Hirsch, Baird, & Bartlett, 
2014).  Those with psoriasis tend to have a higher mean age, are more often of non-
Hispanic white background, suffer from frequent mental distress, depression, arthritis, 
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and obesity (Hemlock et al., 2014).   The National Foundation of Psoriasis (2008) further 
reports that psoriasis is clearly linked with systemic comorbidities, such as cardiovascular 
disease and events, hypertension, diabetes, as well as other immune-related diseases.  
Psoriasis has also been associated with an increased risk for lymphoma, the strongest risk 
was for Hodgkin’s lymphoma, particularly with increased severity of psoriasis (Gelfand 
et al., 2006). 
A systematic review of the economic burden of psoriasis was published in 2015 
(Brezinski, Dhillon & Armstrong).  The review concludes that patients with psoriasis 
incur annual health care costs that are significantly greater than those of the general 
population and may amount to $135 billion annually. In the United States, the economic 
burden of psoriasis is substantial because this disease results in considerable negative 
physical, psychiatric, and social consequences. The direct psoriasis costs ranged from 
$51.7 billion to $63.2 billion, the indirect costs ranged from $23.9 billion to $35.4 billion, 
and medical comorbidities were estimated to contribute $36.4 billion annually in 2013.  
Patients with psoriasis would pay a lifetime cost of $11,498 for relief of physical 
symptoms and emotional health (Brezinski et al., 2015). 
Celiac Disease.  Celiac disease is one of the recognized immune-mediated 
inflammatory diseases, which is caused by a permanent intolerance to the ingestion of 
gluten-containing cereals, wheat, rye, and barley, in genetically pre-disposed individuals 
(Catassi et al., 2007).  Population based studies indicate that the prevalence of CD is 
approximately 0.5-1% in Western European and American populations (Tonutti & 
Bizzaro, 2014), and the frequency of CD is substantially increased in patients who have a 
first-degree family member affected with CD (Rubio-Tapia, Hill, Kelly, & Calderwood, 
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2013).  In patients with CD, the chronic intestinal damage over time carries risk for 
adverse health consequences and increased mortality, including an increased risk for 
malignancies such as small-bowel adenocarcinoma, cancer of esophagus, B-cell and T-
cell non-Hodgkin lymphomas, and in particular intestinal T-cell lymphomas (Rubio-
Tapia et al., 2013).  The evidence also suggests that a consequence of untreated CD and 
chronic malabsorption of nutrients is an increased prevalence of low bone mineral 
density, risk for fractures, and micronutrient deficiencies including iron, folic acid, 
vitamins B12 and B6, copper, zinc, and carnitine (Ludvigsson et al., 2014; Rubio-Tapia 
et al, 2013).  Women with CD have an increased risk of infertility, spontaneous abortions, 
preterm deliveries, and delivery of low birth weight infants (Rubio-Tapia et al., 2013).  It 
is estimated that 83% of Americans who have celiac disease are undiagnosed or 
misdiagnosed with other conditions (Fasano et al., 2003).  The time from onset of 
symptoms to celiac disease diagnosis averages 10 years in the US (Green & Jabri, 2003).   
While prevalence is of CD is on the rise, the economic implications of CD are 
only just emerging.  A 2010 population-based study using administrative data for a cohort 
of celiac disease cases and matched controls from Olmsted County, Minnesota were used 
to compare direct medical costs one year pre- and post-coeliac disease diagnosis.  The 
study found that average total costs for patients were reduced by $1,764 in the year 
following diagnosis, with a pre-diagnosis cost of $5023 versus a post-diagnosis cost of 
$3259 (Long et al., 2010).  While additional economic studies are necessary, these results 
highlight the importance of early diagnosis and treatment, which may prevent 
complications and reduce the economic burden of the disease. 
Rheumatoid Arthritis.  RA is characterized by inflammation of the synovial 
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tissue, which if left untreated, progresses to permanent structural damage and long term 
disability (Emery et al., 2002).  Epidemiological studies of RA indicate a population 
prevalence of 0.5-1.0% in Northern European and North American countries (El-
Gabalawy, Guenther, & Bernstein, 2010).   According to the CDC (2016), an estimated 
1.5 million (0.6%) of US adults aged greater than 18 years had RA in the year 2005.  
Data from the past decade indicate that the incidence of RA in women appears to be 
rising after four decades of decline (CDC, 2016; El-Gabalawy et al., 2010).   
Unchecked disease progression in the RA patient increases the incidence of death 
due to infection, renal failure, non-Hodgkin’s lymphoma (Emery et al., 2002) (Johns 
Hopkins Arthritis Center, 2016) and cardiovascular disease (John’s Hopkins Arthritis 
Center, 2016).  Cardiovascular disease, including ischemic heart disease and stroke, 
accounts for approximately one-third to one-half of RA-related deaths, and infection is 
responsible for approximately one-fourth of RA associated deaths (CDC, 2016).   Those 
with RA who remain untreated are twice as likely to die as compared to those without RA 
of the same age (CDC, 2016; Johns Hopkins Arthritis Center, 2016). Additional risks 
associated with RA are anemia, osteoporosis and depression (Johns Hopkins Arthritis 
Center, 2016) and the possibility of partial or total joint replacement surgeries (Kumar, 
Karthik, Gayathri, & Sivasudha, 2016).  Approximately 90% of patients with RA have 
some form of disability within two decades of onset (Emery et al., 2002). 
In 2012, there were 9,100 hospitalizations with RA listed as the principal 
diagnosis (Birnbaum et al., 2010).  Women and people aged 45 years and older accounted 
for the majority of these stays.  A study utilizing administrative claims databases 
covering privately insured and Medicare and Medicaid beneficiaries in the US during the 
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year 2005 were used to estimate the comprehensive cost of RA patients to society and 
individual stakeholders (Birnbaum et al., 2010).  According to the study, total hospital 
charges amounted to $374 million, with a mean charge of $41,000 per person.  Direct 
out-of-pocket medical costs for patients were estimated to be $8.4 billion, while indirect 
costs were estimated to be $10.9 billion, including earning losses, disability payments 
and decreased productivity.  Finally, the cost of quality of life deterioration and 
premature mortality were calculated to be approximately $39.2 billion (Birnbaum et al., 
2010).  Early detection and treatment of RA improve the long term patient outcomes and 
economic burden of this disease (Emery et al., 2002). 
Crohn’s Disease.  Crohn’s disease is a chronic, relapsing inflammatory bowel 
disease (IBD) that may potentially affect any portion of the gastrointestinal tract from the 
mouth to the anus.  This condition is characterized by progressive bowel damage 
associated with impaired functioning (Peyrin-Biroulet, Loftus, Colombel, & Sandborn, 
2010).  The highest prevalence for CrD has been found for Europe, 322 per 100,000 
people and in North America, 319 per 100,000 people (Laass, Roggenbuck, & Conrad, 
2014).   According to the Crohn’s & Colitis Foundation of America ([CCFA], 2016), 
Crohn’s disease may affect as many as 700,000 Americans.  CrD is not gender-biased; 
men and women are equally likely to be affected.  Further, the disease may appear at any 
age, although CrD is more prevalent among adolescents and young adults between the 
ages of 15 and 35 (CCFA, 2016). 
Patient’s with CrD may suffer from cardiovascular, hepatic, biliary, pancreatic, 
and digestive co-morbidities, as well as metabolic issues and psychiatric problems (San 
Roman & Munoz, 2011) since symptoms have a substantial impact on quality of life.  
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Blockage of the intestine due to swelling and scar tissue is the most common 
complication of Crohn’s (CDC, 2014).  Patients with CrD are at risk for early small 
bowel and colorectal cancer (Baumgart & Sandborn, 2012).  Studies also link 
extraintestinal inflammatory symptoms with CrD in the eyes, skin or joints (Lichtenstein, 
Hanauer, & Sandborn, 2009), as well as ankylosing spondylitis, non-drug induced 
osteoporosis, and other inflammatory-mediated immune diseases (Baumgart & Sandborn, 
2012).  With initiation of corticosteroid therapy, up to 38% of CrD patients will require 
surgery within one year (Lichtenstein et al., 2009).  Mortality risk has been calculated as 
over 50% greater than the general population (Canavan, Abrams, & Mayberry, 2007). 
In addition to associated co-morbidities and quality of life issues, the economic 
burden on the individual and the United States is substantial.  A systematic literature 
review of the costs of CrD in Western industrialized countries was conducted for the year 
2006 (Yu, Cabanilla, Wu, Mulani, & Chao, 2008).   Findings indicated that direct 
medical costs per year were $18,022-$18,932 per patient in the United States.  
Hospitalizations accounted for 53-66% of these direct medical costs, with a per-
hospitalization rate of $37,459.  The total economic burden of CrD was estimated to be 
between $10.9 and 15.5 billion in the United States (Yu et al., 2008). 
Summary.  By the numbers alone, it is clear that autoimmune disorders, on both 
a collective and individual level, should constitute a national, if not global, health crisis 
and that additional scrutiny to this category of diseases needs to be made.  It is critical 
that new methods for facilitating earlier diagnosis of these diseases be developed.  Earlier 
identification of diseases would lead to the initiation of treatments earlier in the course of 
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disease, with the hopes to stave off as much organ destruction as possible, reducing the 
long-term consequences, and costs, of the diseases. 
1.3 Analysis of Current Practice 
General Discussion.  Obtaining a diagnosis for a particular autoimmune disease 
is typically a long and stressful process for most patients.  Many of the initial signs and 
symptoms, such as fatigue, joint and muscle pain, fever or weight change (NIH, 2005) are 
vague and suggestive of many diagnoses.  Practitioners end up treating the symptoms, 
without further regard for the etiology of these symptoms, while the disease continues to 
progress unchecked.   Patients are often required to see multiple practitioners and 
specialists before they have been able to get answers and a definitive diagnosis.  
According to the AARDA (2011), patients, on average, spent five years seeking a 
diagnosis; 46% of patients report being told that they were “constant complainers” or 
“too concerned with their health” (p. 9).  
Diagnosis of an autoimmune disorder begins with a meticulous health history, 
including a careful family history, which might point to a familial tendency toward 
autoimmunity.   The general concept of shared autoimmunity within families, or the 
“kaleidoscope of autoimmunity (Somers, Thomas, Smeeth & Hall, 2009, p. 749)” has 
gained acceptance among researchers, and should be a cornerstone of autoimmunity 
identification.   A careful social history should also be documented, which may help to 
identify the patient’s environmental or occupational exposures.  Additionally, a complete 
physical evaluation has assisted the practitioner in more fully understanding the patient’s 
issues (U.S. Department of Health and Human Services, Office on Women’s Health, 
2010).   
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Laboratory testing remains fundamental to the diagnosis of AI disease in today’s 
healthcare setting (Castro & Gourley, 2010).  Unfortunately, no one specific test exists to 
diagnose autoimmunity.  Multiple tests may be run to help support a diagnosis of 
autoimmunity, such as the complete blood count (CBC), comprehensive metabolic panel 
(CMP), inflammatory markers, autoantibodies, flow cytometry, cytokine analysis, and 
HLA typing (Castro & Gourley, 2010).  Additionally, non-specific tests, such as the 
erythrocyte sedimentation rate (ESR), serum complement markers, ferritin, fibrinogen, 
albumin and C-reactive protein (CRP), help to indicate a state of inflammation and allows 
the practitioner to evaluate disease activity (Castro & Gourley, 2010).   However, 
possessing the knowledge about which tests are available for the 80-100+ AI diseases, 
and how to interpret them, continues to be a challenge for practitioners today. 
In today’s health care arena, AI diseases are managed as individual entities, via 
disease-specific profiles, as opposed to a general immune-related profile (Rahman et al., 
2010).  Guidelines have been developed to help practitioners with the diagnosis and 
treatment of psoriasis, CD, RA and CrD.  The standards of care and current diagnostic 
approaches for these four IMIDs will be discussed below. 
Psoriasis.  Psoriasis commonly presents in the primary care setting (Krueger & 
Bowcock, 2005) and is a chronic, inflammatory, papulo-squamous skin disease.  
Hyperplasia of skin epithelial cells lead to well-circumscribed, raised, red lesions, with 
loosely adherent silvery white scales.  Common locations are the knees, elbows and 
scalp.  Approximately 10-30% of patients also develop psoriatic arthritis (PsA), a painful 
joint condition (Aldredge, 2015).   
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While a plethora of guidelines exist to direct the management and treatment of 
psoriasis, no published diagnostic criteria have been developed.  Diagnosis is dependent 
primarily on the practitioner’s recognition of characteristic skin and lesion patterns, using 
a subjective, qualitative assessment of the patient’s skin (Menter et al., 2008; 
Raychaudhuri, Maverakis, & Raychaudhuri, 2014).  A timely and proper diagnosis, 
therefore, is based wholly upon the practitioner’s general knowledge of psoriatic 
morphology and phenotype.   
Johnson and Armstrong (2012) published a set of clinical and histologic 
diagnostic guidelines for psoriasis, specifically for non-dermatologist practitioners.  The 
authors acknowledge that while no established criteria exist for skin-limited psoriasis, 
trained health care providers should be able to diagnose psoriasis based on clinical 
history and skin examination.   The guidelines (Johnson & Armstrong, 2012) do not offer 
absolute criteria for diagnosing psoriasis, however, they provide a set of 
recommendations that providers should take into consideration during the assessment and 
diagnosis of psoriasis. 
Among these recommendations is to obtain a complete clinical, family and social 
history (Armstrong & Johnson, 2012).  Clinical history should include onset of lesions, 
triggering factors, and associated symptoms (itch, pain, sensitivity, irritation).  Family 
history should be discussed due to genetics and heritability of this IMID.  Social factors 
should also be discussed, due to the association of psoriatic exacerbations with stress, 
smoking and alcohol. Finally, the provider must conduct a full skin examination to 
include the nails, scalp and intertriginous areas.  Health care providers should take special 
notice of the characteristic morphology of the erythema, scaling and induration of lesions 
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(Armstrong & Johnson, 2012).   Although not included in the Armstrong and Johnson 
guidelines, psoriasis classification can include the following morphologies, which may 
present differently in patients and often, present with overlapping clinical findings:  
plaque, inverse, erythrodermic, pustular, guttate, nail disease and psoriatic arthritis 
(Menter et al., 2008).   
Histopathology and skin biopsy, while an option for the diagnosis of psoriasis, is 
not routinely practiced or required.  However, if a question remains on the diagnosis, 
histopathology can be beneficial in distinguishing psoriasis from other inflammatory skin 
diseases (Armstrong & Johnson, 2012). 
Celiac Disease.    Celiac disease is a chronic, immune-mediated inflammatory 
disease that manifests with a range of clinical symptoms in individuals who are 
genetically susceptible.  The consumption of gluten-containing foods triggers an immune 
reaction, and a subsequent, inflammatory state of the duodenal mucosa (Tonutti & 
Bizzaro, 2014).  The immune response is directed against both the exogenous gluten 
antigen and the autoantigen, tissue transglutaminase (tTG), which is a gluten byproduct 
created in the small intestine (Kagnoff, 2006).    
Clinical manifestations of CD can vary widely, and there is no concrete consensus 
regarding which symptoms, laboratory abnormalities or associated diseases require 
further evaluation for CD.   Generally speaking, diagnosis begins with a health care 
provider’s strong suspicion of CD based on the clinical exam and initial laboratory 
results.    
According to the guidelines developed by the American College of 
Gastroenterology, individuals with signs, symptoms or laboratory evidence suggestive of 
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malabsorption, such as chronic diarrhea, weight loss, iron deficiency anemia (IDA) or 
elevated liver enzymes, and/or steatorrhea, postprandial abdominal pain, and bloating, 
should be tested for CD (Rubio-Tapia et al., 2013).   Guidelines from the British Society 
of Gastroenterology (Ludvigsson et al., 2014) state that CD can be suspected in patients 
with mild gastrointestinal symptoms, associated conditions, or those at genetic risk, to 
include symptomatic first-degree relatives of patients with CD, as well as symptomatic 
individuals with Down’s Syndrome and Turner’s Syndrome (Ludvigsson et al., 2014).   
However, since the clinical picture of CD varies, and since many patients only have 
minor symptoms, it can be challenging for health care providers to make that first 
connection, from symptoms to suspicion. 
Further confusing the diagnostic process is the fact that CD has been classified 
into multiple phenotypes:  classic, atypical, silent, latent and refractory (Kagnoff, 2006).  
“Classic” CD is the most commonly described form, and patients present due to 
gastrointestinal symptoms.  Whereas “classic” CD is the most commonly described form, 
“atypical” CD is actually the most prevalent form.  Patients have little to no GI issues, but 
they become identified for other reasons, such as IDA, osteoporosis or infertility.  
“Silent” CD describes the cohort of patients who are asymptomatic, but who diagnose 
positive for CD as a result of serology or biopsy done for another reason.  “Latent” CD 
refers to patients who previously have been diagnosed with CD, who responded to a 
gluten-free diet (GFD) and who retain normal mucosal histology.  “Refractory” CD 
represents patients with true CD, who no longer respond to a GFD. (Kagnoff, 2006; 
Tutonni & Bizarro, 2014).  
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Regardless of how a patient comes to the attention of the practitioner as 
potentially having CD, the next steps in diagnosis are well agreed upon.  The first step in 
diagnosis is serology, followed by a biopsy, which is considered to be the gold standard 
for CD diagnosis (Green & Jabri, 2003; Kagnoff, 2006; Ludvigsson et al., 2014; Rubio-
Tapia et al., 2013; Tonutti & Bizzaro, 2014).  The Immunoglobulin A (IgA) anti-tissue 
transglutaminase (tTG) antibody is the preferred serological test for individuals over the 
age of 2 years.  Both the sensitivity and specificity of the IgA-tTG for untreated CD is 
approximately 95% (Kagnoff, 2006; Rubio-Tapia et al., 2013).  If IgA deficiency is a 
concern, occurring in 1.7%-2.6% of patients with celiac disease (Green & Jabri, 2003), 
total serum IgA should be included in the panel and both IgA and IgG-based testing may 
be initiated to include the IgG-deamidated gliadin peptides (DGPs) (Green & Jabri, 2003; 
Rubio-Tapia et al., 2013).  With known IgA deficiency, both IgG-DGPs and IgG-tTG 
serology may be tested.   Finally, if serology is negative, but suspicion for CD is high, 
intestinal biopsy should be pursued (Green & Jabri, 2003; Kagnoff, 2006; Ludvigsson et 
al., 2014; Rubio-Tapia et al., 2013; Tonutti & Bizzaro, 2014).    
The intestinal biopsy remains the gold standard in diagnosis because results 
reflect the varying degrees by which mucosal villi have been affected over the course of 
the disease.  The Marsh-Oberhuber classification of architectural changes in the intestine 
outline three categories of lesion:  “Type 1” describes an infiltrative lesion,  “type 2” an 
infiltrative-hyperplastic lesion, and “type 3” reports mild, moderate and total levels of 
villous atrophy (Tonutti & Bizzaro, 2014).  Multiple samples should be taken from the 
second or third portion of the duodenum and at least one sample from the duodenal bulb 
(Tonutti & Bizzaro, 2014). 
		 18	
In the setting where results from the aforementioned tests are not clear, or for 
patients already on a GFD, individuals can be genotyped for the gene pairs that encode 
HLA class II heterodimer HLA-DQ2 or HLA-DQ8.  Almost all patients with CD have 
either DQ2 (~95% of CD patients) or DQ8 (the remaining ~5% of CD pts) and the 
absence of both of these DQ alleles provide a negative predictive value for the disease of 
close to 100% (Kagnoff, 2006; Green, 2003; Ludvigsson et al., 2014).   
Rheumatoid Arthritis.   The three major pathways for this immune-mediated 
inflammatory disease include bone degradation, cartilage and synovial destruction, which 
lead to severe disability and premature mortality (Aletaha et al., 2010).  While the precise 
etiology and pathophysiology of RA is not completely understood, at least 16 different 
cytokines, autoantibodies and other mediators are implicated in the disease process 
(Kumar et al., 2016).  The initial immune response, the pre-articular phase, begins with 
the generation of autoantibodies against own tissue components.  During the transition 
phase, the introduction of autoantibodies and autoantigens in the articular joints becomes 
evident, causing joint destruction to occur symmetrically to joints all over the body, 
although the distal interphalangeal and cervical spine is typically spared (Kumar et al., 
2016).  Permanent structural damage occurs early in the disease course of RA and early 
intervention with disease modifying anti-rheumatics drugs (DMARDs) treatment is 
critical toward slowing the progression of joint damage, improving quality of life and 
long term outcomes for patients (Emery et al., 2002).  
The American College of Rheumatology (ACR) and the European League 
Against Rheumatism (EULAR) collaborated to update the classification criteria for RA 
that was last published in 1987 (Cohen & Emery, 2010).   The criteria were developed to 
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help researchers classify newly presenting patients and to help determine which patients 
would benefit from early treatment (Aletaha et al., 2010).   The expert panel identified the 
following mandatory criteria:  pattern and extent of joint involvement, serology 
(rheumatoid factor (RF) and anti-cyclic citrullinated protein (ACPA)), acute-phase 
response (C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR)) and 
duration of symptoms (Aletaha et al., 2010; Neogi et al., 2010).  Two criteria were 
deemed essential.  First, the patient must present clinically with joint swelling in at least 
one joint, indicating synovitis, and second, there must also be an absence of another 
condition that could explain the patient’s symptoms.  Differential diagnoses include 
multiple disorders such as psoriatic arthritis, systemic lupus erythematous (SLE), 
osteoarthritis and gout.  The authors of the classification criteria suggest that if it is 
unclear to the provider which relevant differential diagnoses to consider, a rheumatologist 
should be consulted (Aleteha et al., 2010).   
The remaining four criteria each contribute differently to the probability of 
developing RA and were weighted accordingly during the criteria development (Aleteha 
et al., 2010).  The table below shows the criteria and scoring, with a required score of 6 or 
greater to be classified as having definite RA. 
Table 1.1 The 2010 American College of Rheumatology/European League Against 
Rheumatism Classification Criteria for Rheumatoid Arthritis 
 
The 2010 American College of Rheumatology/European League Against Rheumatism 
classification criteria for rheumatoid arthritis 
Target population (who should be tested?)  Patients who: 
1) Have at least 1 joint with definite clinical synovitis (swelling), 
2) With the synovitis not better explained by another disease. 
 
Classification criteria for RA (score-based algorithm):  add score of categories A-D: 
a. A score of ≥ 6/10 is needed for classification of a patient as having definite RA. 
A.  Joint Involvement 
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1 large joint 0 
2-10 large joints 1 
1-3 small joints (with or without large joint involvment 2 
4-10 small joints 3 
> 10 joints (at least 1 small joint) 5 
B. Serology  
Negative RF and negative ACPA 0 
Low-positive RF or low-positive ACPA 2 
High-positive RF or high-positive ACPA 3 
C. Acute-phase reactants (at least 1 test result required for classification) 
Normal CRP and normal ESR 0 
Abnormal CRP or abnormal ESR 1 
D. Duration of symptoms 
< 6 weeks 0 
≥ 6 weeks 1 
(Reproduced from Aletaha et al., 2010) 
 Although not included in the new classification criteria, radiograph imaging is 
used to assess the structural damage associated with RA, and continues to be the best 
method for collecting data on joint erosions and bone density.  Other markers 
traditionally used by providers to diagnose RA, such as the assessment of morning 
stiffness and the metacarpal “squeeze test” (Emery et al., 2002), have also been excluded 
from the classification criteria. 
 One point must be elucidated about the classification criteria.  These criteria were 
deliberately labeled “classification,” as opposed to “diagnostic” criteria, in order to 
provide a standardized approach for determining which patients presenting with 
undifferentiated synovitis, would have the highest probability of persistent or erosive RA 
(Aletaha et al., 2010).  As such, the authors acknowledge that the criteria may in fact be 
used as a tool for diagnosis, but that easier-to-use tools are in development through 
another joint effort by ACR/EULAR for primary care providers.   
Crohn’s Disease.  Crohn’s disease is a chronic, progressive, destructive 
inflammatory bowel disease (IBD) of the GI tract, manifesting anywhere from the mouth 
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to the anus.  Ulcerative colitis (UC) is the second disease included in the IBD 
classification.  By comparison to CrD, which is intermittent inflammation and can attack 
all bowel wall layers, UC is a continuous inflammation that it is limited to only the 
innermost layer of the intestinal linings in the colon and rectum (CCFA, 2016).   Both 
IBDs are characterized by periods of disease activity interspersed with periods of 
remission.  Symptoms of both CrD and UC may include fever, bloating, cramping, 
nausea, vomiting, severe diarrhea, bloody stool, abdominal pain, weight loss and fatigue.  
CrD patients may also have mucous in their stool (Laass et al., 2014).   Patients can have 
symptoms for many years prior to diagnosis (Burgmann et al., 2006; Pimentel et al., 
2000). 
The rationale for defining early Crohn’s disease is to modify the clinical course of 
the disease and intervene prior to the onset of bowel damage in the form of stricture, 
fistula, or abscess.  However, approximately one-fifth of adult patients already have 
evidence of structuring or penetrating intestinal complications at diagnosis (Peyrin-
Biroulet et al., 2010).  CrD is a seronegative IMID, meaning there is no direct serological 
test for detecting disease activity.  And presently, there is no gold standard for CrD 
diagnosis.  Diagnosis integrates patient information and physical exam with objective 
data from a combination of laboratory, radiologic, endoscopic and histologic findings 
(Laass et al., 2014; Peyrin-Biroulet et al., 2010; Van Assche et al., 2009; (Baumgart & 
Sandborn, 2012).   Genetic testing is not currently recommended (Lichentstein, 2009; 
Peyrin-Biroulet, 2010; Van Assche et al., 2009).   
The most common presenting CrD symptom is chronic diarrhea, defined as a 
decrease in fecal consistency for more than 4 to 6 weeks (Laass et al., 2014).  Abdominal 
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pain is seen in about 70% of patients before diagnosis, and approximately 60% of 
patients experience weight loss (Van Assche et al., 2009).  In approximately 10% of 
patients, the presenting complaint is a perianal fistula (Van Assche et al., 2009).  
Providers must take a complete medical history itemizing symptoms and inquire about 
family history, as first-degree relatives of patients with IBD have a 10-15 fold risk for 
also having IBD (Laass et al., 2014).  A full history should also include information about 
recent travel, food intolerances and medications.  Attention should be paid to proven risk 
factors including smoking and recent infectious gastroenteritis (Van Assche et al., 2009).   
Physical examination includes general well-being, vital signs, body weight, BMI, 
abdominal tenderness or distention, palpable masses, perineal and oral inspection, rectal 
digital examination (Van Assche et al., 2009; Laass et al., 2014) plus signs of 
extraintestinal disease.  Extraintestinal manifestations might present as joint pain, 
swelling, redness or stiffness, erythema nodosu, or redness of the eye (Laass et al., 2014).    
Clinical laboratory testing continues the inflammatory status assessment, although 
of and by themselves, labs are not enough to differentiate CrD from UC or enteric 
infection.  The initial lab investigations support GI inflammation and are used as an 
adjunct to diagnosis (Van Assche et al., 2009).  Patients should be assessed for anemia, 
fluid depletion and signs of malnutrition or malabsorption via the complete blood count 
(CBC).  Anemia and thrombocytopenia represent the most common changes in CBC 
evaluation of patients with CrD (Van Assche et al., 2009).  CRP and ESR are non-
specific acute phase inflammatory markers that should be evaluated.  Fecal calprotectin 
or lactoferrin provides an estimation of fecal inflammation by measuring for the presence 
of fecal leukocytes (Lichtenstein et al., 2009).  Fecal calprotectin has a positive predictive 
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value of 85-90% in distinguishing IBD from irritable bowel syndrome (IBS).   Stool 
cultures are beneficial for ruling out infectious colitis caused by viral, bacterial or 
parasitic sources (Laass et al., 2014; Van Assche et al., 2009; Lichentenstein et al., 2009).   
Providers must also consider lactose intolerance and celiac disease in their list of 
differential diagnoses.   
Upper or lower GI endoscopy is used to confirm the diagnosis of CrD, assess 
disease location, and obtain tissue for pathological examination (Laass et al., 2014; Van 
Assche et al., 2009).   However, the initial symptoms frequently determine the order of 
subsequent testing.   For example, colonoscopy, intubation of the terminal ileum, is the 
most appropriate initial test for patients presenting with predominant diarrhea, and is used 
to establish the diagnosis of ileocolonic CrD.  On the other hand, imaging studies may be 
more appropriate for those presenting with abdominal pain.   Magnetic resonance 
enterography is the initial test used to evaluate the small intestine. Wireless video 
endoscopy, or video capsule endoscopy (VCE), may also be useful for detecting small 
bowel involvement (Laass et al., 2014; Van Assche et al., 2009). 
1.4 Statement of Problem/Purpose 
In adult patients aged 18 years and greater with psoriasis, does screening for 
celiac disease, rheumatoid arthritis, and crohn’s disease improve early detection for these 
autoimmune disorders?  The Population (P) in this question is adult patients aged 18 
years and greater in primary care and outpatient settings.  The Intervention (I) is the 
development and implementation of a simple screening tool in adults patients with 
psoriasis for celiac disease, rheumatoid arthritis and crohn’s disease.  There is no 
Comparison (C) for this background-type question.  The Outcome (O) is demonstrating 
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improved early detection of celiac disease, rheumatoid arthritis and crohn’s disease in 
adult patients with psoriasis.   Table 1.1 contains the definitions of population, setting, 
intervention, and outcome as defined by Melynk & Fineout-Overholt (2011).   The 
purpose of this project is to conduct a substantive review of the literature to determine if 
screening primary care patients with psoriasis will improve early detection of celiac 
disease, rheumatoid arthritis, and Crohn’s disease. 




Setting Current Practice Intervention Outcome 
In adult 
patients over 














detection of celiac 
disease, rheumatoid 
arthritis and Crohn’s 
disease as measured by: 
a provider 
documentation for 
screening those with 
psoriasis for celiac 
disease, rheumatoid 
arthritis and Crohn’s 
disease.  
1.5 Project Questions 
The project was guided by the following clinical questions: 
What is autoimmunity?  What is polyautoimmunity?  What are IMIDs? 
Why is it so difficult for patients with autoimmune diseases to become diagnosed? 
Is there evidence that suggests that individuals with one autoimmune disease are 
more at risk for developing another autoimmune disease? 
Is there evidence that suggests that individuals with psoriasis have a greater risk 
of developing celiac disease, rheumatoid arthritis or Crohn’s disease? 
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What are the current, accepted approaches for diagnosing psoriasis, celiac disease, 
rheumatoid arthritis and Crohn’s disease? 
Would screening patients with psoriasis for celiac disease, rheumatoid arthritis 
and Crohn’s disease improve early detection for these diseases? 
1.6 Definitions 
Adult Patients – Adult patients refer to men and women over the age of 18 years 
seeking health care in a primary care setting. 
Celiac Disease - Celiac disease is an autoimmune disease that causes an 
inflammatory reaction to ingested gluten, a protein found in wheat, rye, and barley.  
When a person has celiac disease, gluten causes the immune system to react in a way that 
can cause intestinal inflammation—irritation or swelling—and long-lasting damage 
(NIH, 2015). 
Crohn’s Disease - Crohn’s disease is an autoimmune disease characterized by 
chronic, relapsing inflammation to any portion of the gastrointestinal tract from the 
mouth to the anus.  Also known as one of the inflammatory bowel diseases (IBD), this 
condition is caused by an abnormal response to the body's immune system which results 
in progressive bowel damage associated with impaired functioning (Peyrin-Biroulet et al., 
2010; CDC, 2014).    
Early Detection - Early detection refers to a screening program that detects 
disease in asymptomatic persons or in symptomatic persons not yet recognized to have 
disease.  Relative to background conditions, screening identifies the affected individual at 
an earlier time point in the natural history of disease (Weissfeld, 2001). 
Health Screening - Health screenings include specific technology (survey 
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questionnaire, physical observation or measurement, laboratory test, radiological 
procedure, etc.) that are used to help identify persons with unrecognized disease or 
unrecognized risk factors for disease (Weissfeld, 2001). 
Rheumatoid Arthritis – Rheumatoid arthritis is an autoimmune disease 
characterized by chronic, systemic inflammation of the synovial tissue.  If left untreated, 
RA progresses to permanent structural damage and long-term disability (CDC, 2016; 
Emery et al., 2002). 
Primary Care Providers - A primary care provider (PCP) is a health care 
practitioner who is responsible for monitoring an individual's overall health care needs.  
The PCP's role is to provide preventative care and teach healthy lifestyle choices, identify 
and treat common medical conditions, assess the urgency of medical problems and direct 
the patient to the best place for their care, and make referrals to medical specialists when 
necessary (She, 2012). 
1.7 Chapter Summary 
Research suggests (Cooper, Bynum & Somers, 2009) that individuals with one 
autoimmune disease typically will develop an additional one or more separate, and 
distinct, autoimmune diseases over the course of their lifetime.   Further, links have been 
drawn between psoriasis and celiac disease, rheumatoid arthritis and crohn’s disease 
(Augustin, Reich, Glaeske, Schaeffer & Radtke, 2010; Ali & Warren, 2013; Wu, Nugyen, 
Poon & Herrington, 2012;  Guerin, Zhang, Gauthier, Day & Khan, 2012; Hsu & 
Armstrong, 2012; Makredes, Robinson, Bala & Kimball, 2009; Birkenfeld, Dreiher, 
Weitzman & Cohen, 2009;  Tsai, Wang, Hung, Tsai, Schenkel, Zhang & Tang, 2011).  
Regrettably, practitioners may overlook the associations between these autoimmune 
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diseases, prolonging the diagnostic process (Somers et al., 2009).   The purpose of this 
project is to conduct a substantive review of the literature to determine if screening 
primary care patients with psoriasis will improve early detection of celiac disease, 
rheumatoid arthritis, and Crohn’s disease.		The aim of this project is to assess the utility 
of early screening in patients with psoriasis in order to facilitate earlier diagnosis of CD, 
RA and CrD, which would consequently initiate earlier treatment and improve long-term 
patient outcomes. 
The next step in the evidenced-based practice process is the literature search and 
analysis.  The evidence will be organized using an evidence table.  This process is 





 The goal of this chapter is to appraise and synthesize the evidence for conducting 
the DNP project for changes in practice.  The discussion that follows describes the 
literature search process, and an objective summary and analysis of fourteen research 
articles.   The purpose of this content is to convey the current state of knowledge, and 
significance of, the relationship between psoriasis and the three IMIDs of interest (celiac 
disease, rheumatoid arthritis, and Crohn’s disease) to healthcare providers and decision 
makers.  
2.2 Search Methodology  
Evidence-based practice mandates that clinical decisions be driven by the most 
current research studies, the clinical experience of the practitioner, and patient 
preferences (Melnyk & Fineout-Overholt, 2011).  Evidence-based research begins with a 
question of interest, followed by the systematic collection, appraisal and synthesis of 
evidence.  The following information presents the search strategy employed for the 
question:  in adult patients aged 18 years and greater with psoriasis, does screening for 
celiac disease, rheumatoid arthritis, and Crohn’s disease improve early detection for these 
autoimmune disorders?		 
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This is a background-type PICO question and according to Melnyk and Fineout-
Overholt (2011), the following types of studies are appropriate for review, in descending 
order of level of evidence:  synthesis of cohort study or case control studies, single cohort 
studies or case-control studies, meta synthesis of qualitative or descriptive studies, single 
qualitative or descriptive studies, and expert opinion.   A search of databases was 
performed, accessed through the University of South Carolina’s online library.   The 
Cumulative Index for Nursing and Allied Health Literature (CINAHL), PubMed-
Medline, Medline OVID, Cochrane Library, Web of Science, Essential Evidence Plus, 
Nursing Resource Center, Health Source:  Nursing/Academic Edition, Dissertations and 
Thesis, Annual Reviews, as well as Google Scholar were included in the search.  
Reference lists of acceptable papers were also manually examined for additional 
resources.    
The main search terms were “psoriasis” and “autoimmunity.”  Limitations were 
set for the years 2006-2016, in order to review the most up-to-date research and evidence 
on the topic, and for English-only papers, to eliminate language barriers.  Additional 
cross-searching terms utilized were “co-autoimmunity,” “co-existence,” “association,” 
“pan autoimmunity,” “immune mediated inflammatory diseases,” or “IMIDs,” and 
“screening.”  Finally, “psoriasis” was searched specifically against the three AI disorders 
of interest for this project:  “celiac disease,” “Crohns disease,” and “rheumatoid arthritis.” 
 A total of fourteen papers were selected.   Levels of evidence were appraised 
using the Scottish Intercollegiate Guidelines Network (SIGN) rating system (Appendix 
A).  The rating scale ranges from 1++, the highest level of evidence, reserved for high 
quality meta-analysis, systematic reviews of RCTs, or RCTs with a very low risk of bias, 
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to 4, reserved for expert opinion, the lowest level of evidence.  Four retrospective cohort 
studies with control groups were found (level of evidence 2+).  Four case-control studies 
(level of evidence 2+), one cross-sectional study (level of evidence 3), two meta-analysis 
of genetic studies (level of evidence 1+), one meta-analysis of population based studies 
(level of evidence 1+), one prospective cohort study (level of evidence 2+), and one 
expert review paper (level of evidence 4) were included.    
2.3 Analysis of the Evidence 
Evidence was organized in table format with the following headings:  brief 
reference, type of study/quality ratings, methods, threats to validity/reliability, findings 
and conclusions (Appendix B).  The table was developed to consolidate methodological 
and outcome summaries from the selected articles and used for the purpose of synthesis 
and analysis.   Each evidence-based, peer reviewed article was systematically appraised 
on the individual level, followed by an overall summary of findings.  The four genetic 
studies are presented first, followed by the population-based studies.   For the purposes of 
this literature review, when studies include multiple AI disorders, only the four AI 
diseases directly related to this study, psoriasis, celiac disease, rheumatoid arthritis, and 
Crohn’s disease, will be discussed. 
2.4 Genetic Studies.    
Four of the fourteen research articles included in this review can be classified as 
genetic studies.   What follows is a brief discussion to foster a basic understanding of 
single nucleotide polymorphisms (SNPs), the main concept in each of the studies.   
From a top down perspective, all cells in the body contain a nucleus, which then 
contains 23 pairs of chromosomes.  Each tightly packed chromosome unravels to reveal a 
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double helix of deoxyribonucleic acids, or DNA.  The DNA double helix is composed of 
a long sequence of nucleotide base pairings, adenine (A), thymine (T), guanine (G) and 
cytosine (C).  These nucleotide bases link in a very specific way: A always pairs with T, 
and C always pairs with G.  Distinct sequences of these nucleotides organize the 
chromosomes into sub-units, which are genes.  Genes provide the cell with the 
instructions that dictate cell function (National Human Genome Research Institute, 2015). 
A SNP is defined as a single nucleotide base change in a DNA sequence that 
occurs in a significant proportion (more than 1 percent) of a large population (University 
of Utah Health Sciences, 2016).  To make an analogy, 99% of the population has a 
sequence for “Marie,” while approximately 1% has a sequence for “Maria.”  Today’s 
challenge for researchers is to identify SNPs, or the “Maria’s,” that correlate with a 
particular effect in patients.  Genetic association studies, such as the ones to follow, 
compare the frequency of genotypes at genetic marker loci, usually single-nucleotide 
polymorphisms (SNPs), in individuals with and without a given disease trait from a given 
population.  The objective of these association studies is to determine whether a 
significant statistical association exists between the disease trait and the genetic marker 
(Clarke, Anderson, Peterson, Cardon, Morris & Zondervan, 2011).  Reliable SNPs could 
serve as predictive gene markers that inform decisions about numerous aspects of 
medical care, including specific disease diagnosis, predisposition to disease, and the 
effectiveness of various drugs and adverse reactions to specific drugs (University of Utah 
Health Sciences, 2016).    
Association of SNP Gly307Ser (rs763661) with Psoriasis, CD & RA.  Qiu, 
Khang, X. Qiu, Zhou and Li (2013) conducted a meta-analysis to evaluate the 
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relationship between the non-synonymous single nucleotide polymorphism (SNP) 
Gly307Ser (rs763361) in the CD226 gene that has been reported to be associated with 
several AI diseases, including psoriasis, celiac disease, and rheumatoid arthritis.  Whether 
the presence of this t allele rs763361 confers a risk for multiple AI diseases remains 
under investigation.  This study was rated a 1+.   
The authors conducted a comprehensive search of the U.S. National Library of 
Medicine’s PubMed and Embase databases for studies that fulfilled the following 
inclusion criteria:  (1) were based on case-control design, (2) evaluated the association of 
the Gly307Ser (rs763361) polymorphism with multiple autoimmune disorders, (3) 
disease diagnosis followed the diagnosis criteria of the World Health Organization 
(WHO), (4) genotype frequencies were provided, (5) authors provided sufficient data for 
estimating an odds ratio and their 95% confidence interval (CI), and (6) papers were 
published with full text articles (Qui, Z., Zhang, X. Qui, Zhou & Li, 2013).  Seven 
published studies met the inclusion criteria, covering 7,876 cases and 8,558 controls.  The 
sample sizes varied from 90 to 2,838 and included two European, two Asian, one South 
American and three Estonian studies.  The studies utilized three different genotyping 
methods, polymerase chain reaction-restriction fragment length polymorphism (PCR-
RFLP), TaqMan genotyping and SNPlexTM (Qui, et al., 2013).     
Qui et al. (2013) used STATA 12.0 software for statistical analysis and estimated 
the association between CD226 Gly307Ser (rs763361) polymorphism and multiple AI 
diseases using crude odds ratio (OR) with 95% CIs.  As is appropriate for meta-analyses, 
the authors assessed the degree of inconsistency in the studies' results, or between-studies 
heterogeneity, using Q-test and I2 statistics.  The DerSimonian and Laird random-effect 
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model calculated pooled estimates in case of significant heterogeneity.  In cases without 
obvious heterogeneity, the Mantel-Haenszel fixed-effect model estimated a summary OR.   
The evaluation of the association of CD226 Gly307Ser (rs763361) polymorphism 
with multiple AI diseases demonstrated an overall OR 1.19 (95% CI: 1.12-1.27, 
Pheterogeneity=0.136), indicating that a significantly increased multiple AI disease risk was 
found to be associated with the t allele rs763361 (Qui et al., 2013).   The authors also 
conducted a subgroup analysis by ethnicity, where increased risks were found for South 
Americans (OR=1.31, 95% CI=1.17-1.48, Pheterogeneity = 0.644), Asians (OR=1.23, 95% 
CI=1.11-1.38, Pheterogeneity = 0.690), and Europeans (OR=1.13, 95% CI=1.04-1.24, 
Pheterogeneity = 0.085) (Qui et al, 2013).    
Although heterogeneity was detected in both the overall comparison and in the 
subgroup analyses, none were notable (Pheterogeneity = 0.136, I2=29.3% in overall 
comparsion; Pheterogeneity = 0.644, I2=0.0% in South Americans; Pheterogeneity = 0.690, 
I2=0.0%; Pheterogeneity = 0.085, I2=46% in Europeans).   Meta-regression analysis was 
performed to explore sources of heterogeneity across studies when statistical 
heterogeneity was detected.  Publication year was closely related to the heterogeneity in 
allele comparison (I2=11.9%, P=0.036), while racial descent, study sample size, 
genotyping methods, and controls’ source did not indicate any modifying effect of the 
factor (P>0.05) (Qui et al, 2013).  
Further, Begg’s test suggested no significant publication bias and the Hardy-
Weinberg equilibrium was demonstrated by using the Fisher’s exact test (p < 0.10).  
Finally, the authors conducted a sensitivity analysis to assess the stability of results.  The 
sensitivity analysis indicated that no individual study significantly affected the pooled 
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OR, and that results were statistically robust.  The authors, however, acknowledged 
limitations to this study.  First, this study lacked the original information for the 
individuals in the included studies; as such, data could not be stratified by other variables, 
such as gender, and mean age at onset (Qui et al, 2013).  The lack of original data also 
means that the authors would not have been able to validate each case for the meta-
analysis.  Therefore, the possibility of diagnoses misclassification in the original studies 
cannot be completely excluded.  Second, races other than South American, Asian, 
European and Estonian were not represented in this meta-analysis.  Third, the authors 
note that while their publication bias showed no significance, it cannot be completely 
ruled out due to exclusion of relevant publications that were not indexed by their selected 
databases, PubMed and Embase (Qui et al, 2013).  
The results of this meta-analysis, that a significantly increased multiple AI disease 
risk was found to be associated with the t allele rs763361, highlight the evolving 
comprehension of co-autoimmunity.  It further supports the concept that susceptibility to 
AI diseases may be due to a complex interaction of multiple genes, some of which seem 
to be shared among many of these AI diseases, including psoriasis, celiac disease and 
rheumatoid arthritis. 
15 New Psoriasis Susceptibility Loci.  Tsoi et al. (2013) conducted a meta-
analysis of three GWAs and two independent datasets genotyped on the “Immunochip,” 
to include a total of 10,588 cases (patients with psoriasis) and 22,806 controls.  The 
“Immunochip” is a custom-designed SNP array whose function is to fine-map genome-
wide significant (P<5x10-8) susceptibility loci and to explore replication of thousands of 
SNPs representing additional promising signals.  Tsoi et al. and other investigators of 12 
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distinct autoimmune and inflammatory diseases designed the chip in 2009 (Parkes, 
Cortes, Van Heel & Brown, 2013).   
The Immunochip consists of 196,524 SNPs compiled from variants identified in 
previous GWAS of 12 different IMIDs.  Each disease-focused group involved in the chip 
design were then allowed to submit approximately 3000 additional SNPs in order to 
evaluate signals that were deemed promising or that had not quite met genome-wide 
significance in previous studies (Tsoi et al, 2013).  The main objective of this study was 
to increase understanding of the genetic architecture of psoriasis, identify new genetic 
determinants of psoriasis, and to relate them to other AI diseases (Tsoi et al., 2013).  This 
study has been rated a 1+. 
The authors performed a meta-analysis from five datasets that were genotyped on 
the Immunochip.  These datasets included three existing GWAS (Kiel, CASP and 
WTCCC2) and two independent European descent case-control datasets, the Psoriasis 
Association Genetics Extension (PAGE) and the Genetic Analysis of Psoriasis 
Consortium (GAPC) (Tsoi et al., 2013).   Prior to meta-analysis, a number of quality 
control steps were taken by the authors in order to identify and remove DNA samples and 
markers that could introduce bias into the study.  SNPs with a call rate below 95% were 
excluded.  Using the HapMap 3 samples as a reference, the authors performed principal 
component (PC) analysis to identify and remove samples with non-European ancestry.  
Samples with extreme inbreeding coefficients or heterozygosity values were also 
removed, as were duplicate pairs or highly related individuals.  A principle component 
(PC) analysis was also used on each individual dataset to assess for possible population 
stratification; no evidence of stratification between cases and controls within each dataset 
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was found.  Finally, imputation was performed on the datasets in order to increase the 
number of overlapping SNPs between datasets.  SNPs with low imputation quality were 
removed (Tsoi et al., 2013).   
The meta-analysis revealed genome-wide significance (P<5x10-8) for 19 of the 21 
known psoriasis loci.  The analysis demonstrated nominal evidence for the two remaining 
loci.  Fifteen new risk loci for psoriasis were also identified that fulfilled genome-wide 
significance (Tsoi et al., 2013).  Of the total 39 known and new psoriasis susceptibility 
loci included in this study, ten of these loci overlapped with Crohn’s disease, nine with 
celiac disease, and five with rheumatoid arthritis.   A table has been provided below to 
provide a snapshot view of SNPs  (known versus new) relative to disease overlap.  The 
table also includes each SNP combined p-value and meta OR from analysis, as well as 
the notable genes associated with each SNP. 





SNP Combined P-value OR (meta) Notable genes Disease overlap 
rs9988642 1.1×10-26 1.52 IL23R  CrD 
rs62149416 1.8×10-17 1.17 FLJ16341, REL  RA, CrD, CD 
rs27432 1.9×10-20 1.20 ERAP1  CrD 
rs1295685 3.4×10-10 1.18 IL13, IL4  CrD 
 
rs2233278 2.2×10-42 1.59 TNIP1  CrD 
rs12188300 3.2×10-53 1.58 IL12B CrD 
rs582757 2.2×10-25 1.23 TNFAIP3 CD, RA 
rs1250546 6.8x10-7 1.10 ZMIZ1 CD, CrD 
rs34536443 9.1×10-31 1.88 TYK2  CrD 
rs4821124 3.8×10-8 1.13 UBE2L3  CD, RA, CrD 
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Newly Identified Loci 
SNP Combined P-value OR (meta) Notable genes Disease overlap 
rs11121129 
 





2.3×10-12 1.13 RUNX3  CD 
rs9504361 2.1×10-11 1.12 EXOC2, IRF4  CD 
rs2451258 3.4×10-8 1.12 TAGAP   CD, CrD, RA 
rs2700987 4.3×10-9 1.11 ELMO1   CD, RA 
(Tsoi et al., 2013) 
It is important to emphasize that the authors suitably denote a very low threshold 
P-value supportive of genome-wide significance, indicating that the association is not due 
to chance alone.  In a meta-analysis study where a large number of variants are being 
studied, the low P-value is required in order to protect against the production of large 
numbers of false positives (Type I error); however, such a conservative approach may 
therefore cause variants with small real effects to be overlooked, leading to false 
negatives (Type II error) (Thompson, Attia & Minelli, 2011).  To overcome Type II error, 
sample sizes must be large enough to achieve sufficient power to identify such SNPs.  
Using large combined datasets significantly increases the power in GWA studies 
(Thompson, Attia & Minelli, 2011).   
A notable limitation with GWAS studies is that they are only able to detect an 
association for a genomic region, and not causation of a mutation, that may be involved 
in the development of the disease or trait.  Additionally, SNPs typically only explain a 
small fraction of an individual’s risk for the trait (Genetics and Social Science, 2016).  
Tsoi et al. (2013) report that the 41 independent signals with P<5x10-8 collectively only 
account for 14.3% of the total variance in psoriasis risk, or approximately 22% of its 
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estimated heritability.  One explanation for the missing heritability is that complex 
diseases are caused by a large number of causal variants with small effect sizes (Stringer, 
Wray, Kahn and Derks, 2011).  The small effect sizes are reflected in the odds ratios 
reported by this meta-analysis, which can be described to be modest, at best.   
Odds ratios for the individual SNPs ranged from 1.09 (rs645078) to 1.88 
(rs34536443), with one SNP (rs4406273) deviating from this pattern with an OR of 4.32. 
According to Stringer, Wray, Kahn and Derks (2011), ORs from GWA studies are 
typically low to modest, although they may in fact be underestimates of the true 
conditional odds ratios.   
Despite these limitations, GWA studies should be considered foundational 
research in the identification of novel candidate genes, which is especially important in 
traits for which the biological etiology is unknown, such as the IMIDs. 
Genetic Overlap Between Psoriasis and Crohn’s Disease.  Wolf et al. (2008) 
conducted a prospective case-control study in order to investigate the genetic overlap 
between psoriasis and Crohn’s disease.  Specifically, the authors analyzed the 
contribution of CrD genetic determinants to psoriasis susceptibility.  The authors 
approached this study from the perspective that previous linkage studies have already 
repeatedly identified the psoriasis disease susceptibility locus (PSOR1), as well as loci 
PSORS2-10, as regions with overlapping susceptibility to other inflammatory conditions, 
including CrD.   Therefore, 15 CrD susceptibility loci newly identified by genome-wide 
association analysis were assessed for significant disease associations with psoriasis 
(Wolf et al., 2008).  This study has been rated a 2+. 
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Patients were recruited from within the United Kingdom via St. John’s Institute of 
Dermatology in London (n=638), Glasgow Western Infirmary (n=211), and the 
Dermatology Centre, University of Manchester (n=407).  A total of 1,256 patients were 
included in the study, 645 male and 611 female, all of northern European descent and 
with onset of psoriasis vulgaris occurring before 40 years of age.  Less than 1% of the 
patients also had documented CrD.  The patients were matched with 2,938 controls from 
the Wellcome Trust Case-Control Consortium (WTCCC).   Study approval was received 
from three entities, the Guy’s and St. Thomas’ Hospitals Ethics Committee of Kings 
College London, the Salford and Tafford Local Research Ethics Committee and North 
Glasgow University Hospitals NHS Trust Local Research Ethics Committee.  Informed 
consent was obtained from all patients for the use of their DNA sample.  Control 
genotypes were obtained from publicly released data available at the WTCCC (Wolf et 
al, 2008).  
Patient DNA was typed using TaqMan assays and the frequencies of alleles for 
both cases and controls were compared using a X2 test with one degree of freedom.  
Regression analysis was conducted with PLINK software.  Significant disease association 
for three independent CrD markers, rs1203582 (OR=1.14; 95% CI 1.03 to 1.25), 
rs6908425 (OR=1.26; 95% CI 1.12 to 1.42) and rs2836754 (OR=1.17; 95% CI 1.06 to 
1.30), was observed among the psoriasis cases (Wolf et al, 2008).  In other words, three 
of the examined Crohn’s disease SNPs are significantly associated with psoriasis.  
Interestingly, the marker that demonstrated the strongest effect, rs6908425, also maps to 
a gene previously associated with type 2 diabetes (Wolf et al., 2008).  
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Wolf et al. (2008) calculated false discovery rates (FDR), or the proportion of 
discoveries that are false among all discoveries (Benjamini & Hochberg, 1995), for the 
three significant SNP associations.   The authors determined that all three significant 
associations surpassed the 5% FDR threshold (P ≤ 0.01), with two SNPS (rs6908425 and 
rs2836754) exceeding 1% FDR (P < 0.001).  Additionally, Wolf et al. (2008) tested for 
the presence of epistasis between the various disease-associated alleles using a case-only 
test to assess for gene-gene interaction.  Pair wise comparisons of all SNPS resulted in 
non significant X2 values, however, using the same approach to test for interactions 
between HLA-Cw*0602, the strongest determinant of disease risk from the PSOR1 locus, 
against the individual SNPS, suggestive evidence for an interaction with rs12035082 was 
generated (p= 0.02).  Additional, larger patient cohorts would be necessary to validate, or 
invalidate, this epistatic effect.   
The major issues concerning case-control studies design are case-control 
matching and presence of population stratification (Ghosh, 2007).   Studies have shown 
that allelic distributions may vary between different ethic populations.  This highlights 
the importance of selecting cases and controls with similar ethnic background in order to 
ensure that false positive associations do not result.  Wolf et al. (2008) argue that their 
findings are unlikely to be due to population stratification, based on the fact that their 
cases and controls have the same ethnic and geographical origin.  The data generated by 
WTCCC shows that the allele frequencies of SNPs rs12035082, rs6908425 and 
rs2836754 are homogenous across the UK, further invalidating the plausibility that 
associations are due to hidden population structure (Wolf et al., 2008).   
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The results of this study lend additional evidence to suggest that individuals with 
psoriasis are also predisposed to CrD.   This highlights the pleiotropic effects of co-
autoimmunity, in which one gene influences two or more seemingly unrelated phenotypic 
traits. 
IL23R Association with Crohn’s disease, Celiac Disease and Psoriasis.  In 
2006, Duer et al. first identified an association of genetic markers in the interleukin-23 
receptor (IL23R) gene, as well as the intergenic region between IL23R and IL122RB2, 
with inflammatory bowel disease.  Einarsdottir’s et al. (2009) objectives were to 
determine if this association could be replicated with Swedish and Finnish patients with 
IBD.  The authors expanded their study to also assess IL23R’s association with two other 
AI diseases with chronic inflammatory features, psoriasis and celiac disease.  Einarsdottir 
et al. (2009) utilized the Swedish and Finnish cohorts to also study the IL23R/psoriasis 
association; the IL23R/celiac association was studied among Finnish, Hungarian, and 
Italian populations.  This study has been rated a 3. 
Subjects for the IBD portion of the study were recruited from Karolinska 
University Hospital in Stockholm.  A total of 803 patients were selected based on 
fulfillment of established clinical criteria, including endoscopic, radiological and 
histopathological data.  Of these 803 cases, 455 were patients with ulcerative colitis and 
348 were patients with Crohn’s disease.  Controls were randomly selected from 
ethnically matched, unselected individuals (Einarsdottir et al., 2009).   
The celiac disease subjects were recruited from Finland, Hungary, and Italy.  
From Finland, 260 families with celiac disease were enrolled from the University of 
Tampere.  From this sample, 185 families had more than one individual affected with 
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celiac disease (multiplex families), and 75 families had an affected father, mother and a 
child (trios).  The rest of the 165 families had only one affected family member.  Celiac 
disease was diagnosed mostly according to ESPGHAN criteria, however approximately 
1% of the cases were diagnosed based on the presence of disease specific anti-
endomysial antibodies.   
The Hungarian subjects consisted of 400 families, 204 of which were multiplex 
families and 196 trios, plus 270 cases and 270 controls.  The Italian dataset was 
comprised of 139 cases and 198 controls.  Although Einarsdottir et al. (2009) do not 
describe the selection process for their Hungarian and Italian subjects in this publication, 
readers are referred to other studies where this process was duplicated.  
The Psoriasis dataset consisted of 255 Finnish families, 64 multiplex families and 
191 trios, plus 385 affected individuals.  One psoriasis patient from each family was 
randomly selected and matched to a Finnish control.  Again, the authors reference 
another study for a description of the selection process. 
Eight SNP markers were selected based on Duerr’s et al. (2006) study.  All 
genotyping took place at the MAF core facility in Karolinksa Institute, Stockholm, 
Sweden.  The case-control IBD dataset replicated the Duerr et al. (2006) findings with a 
power of approximately 89%.  Of the 8 SNPs assessed, SNP rs11465804*G demonstrated 
the strongest association for the combined dataset including both CrD and UC (p=0.002, 
OR=0.42).   Marker rs1004819 also indicated a strong association with Crohn’s disease 
in the Swedish population (p=0.006, OR=1.43) (Einarsdottir et al., 2009).    
Central to linkage studies is the logarithm of odds (LOD) score analysis (Nyholt, 
2000).  The authors used this calculation to estimate whether the observed degree of 
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concordance of IL23R markers between family members with celiac disease, indicates 
signification genetic linkage between the two (Nyholt, 2000).  LOD scores greater than 3 
traditionally indicate that within the marked region, there is the presence of one or more 
gene loci that influence the phenotypic trait; in other words, a LOD score of 3+ indicates 
1000 to 1 odds that the linkage being observed did not occur by chance.  This is 
considered to be significant linkage (Nyholt, 2000).  The Finnish families demonstrated 
significant linkage for celiac disease (lod=3.24, p=0.00006, 135 individuals), while the 
Hungarian families did not (lod=0.4, p=0.08, 132 individuals) (Einarsdottir et al., 2009).   
Additionally, none of the celiac disease case-control datasets demonstrated significant 
association to any of the IL23R markers (Einarsdottir et al., 2009).    
The psoriasis studies also revealed mixed results.  Fifty-one of the 255 Finnish 
families with psoriasis were informative for linkage, yielding a LOD score of 0.83 
(p=0.03).  However, despite the low score, an association of IL23R with psoriasis was 
confirmed in the Finnish case-controls.  The authors suggest that polymorphisms in both 
IL23R and IL12B, which encodes part of the IL23 cytokine, may collectively be more 
important for susceptibility to psoriasis, than is either on their own (Einarsdottir et al., 
2009).  As such, Einarsdottir et al. (2009) call attention to the fact that anti-IL12/IL23 
antibody treatments improve psoriasis symptoms, which supports their argument that 
multiple components exist in the pathway of this disease. 
2.5 Population Based Studies 
 Psoriasis and Celiac Disease.  Bhatia, Millsop, Debbaneh, Koo, Linos and Liao 
(2014) conducted a meta-analysis of population-based studies examining the co-
occurrence of psoriasis and celiac disease, investigations of celiac disease antibody 
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markers in psoriatic cohorts, and clinical trials examining the therapeutic benefit of a 
gluten free diet (GFD) in patients with psoriasis. The objective of this analysis was to 
examine the evidence that patients with psoriasis are at an increased risk for celiac 
disease and to also review studies evaluating the impact of a GFD on psoriasis 
improvement (Bhatia, Millsop, Debbanch, Koo, Linos & Liao, 2014).  This study has 
been rated a 1+. 
 The authors searched the MEDLINE database via PubMed for articles between 
1960 and 2012, and conducted a manual bibliographical search to identify additional 
studies that warranted inclusion; 23 articles in total met their criteria. Meta-analysis was 
performed in STATA using a random effects model (Bhatia et al., 2014).   
 Three population studies were reviewed, all of which demonstrated that patients 
with psoriasis are at an increased risk for celiac disease (Bhatia et al., 2014).  Fourteen 
studies related to serological celiac disease markers in psoriasis patients were reviewed.  
Of these fourteen, nine studies reported a positive association between celiac disease 
markers, while seven did not find statistically significant evidence for an association.  
Bhatia et al. (2014) caution that the findings in the latter seven studies may be related to 
small study size and lack of control groups.   
Further, Bhatia et al.’s analysis demonstrated a statistically significant relative 
risk of testing positive for IgA anti-gliadin antibody (AGA) in patients with psoriasis, as 
compared to control subjects (ORtotal = 2.36; 95% C.I. 1.15-4.83) (Bhatia et al., 2014).  
The authors are 95% confident that the odds are between 1.15 and 4.83 greater for an 
individual with psoriasis to test positive for IgA AGA than for an individual without 
psoriasis.  
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Finally, the authors examined a number of studies that considered the effect of a 
GFD on psoriasis severity.  Six studies demonstrated that patients with psoriasis, with 
either elevated AGA and/or tTG, showed improvement in psoriatic lesions after a GFD.  
One study utilized a pre- and post-GFD Psoriasis Area Severity Index (PASI) score to 
evaluate changes, revealing a 73% improvement.  In this same study, AGA levels were 
lower in 82% of the psoriasis patients (Bhatia et al., 2014).  The authors highlight an 
interesting result from this study; for the patients with both psoriasis and elevated AGA 
levels, and who experienced improvements after the GFD, all also had normal 
histological results in their pre-GFD duodenal biopsies.  The authors conclude that a GFD 
may be beneficial in patients with psoriasis and gluten-sensitivity (marked by elevated 
AGA levels) even in the absence of biopsy-confirmed celiac disease (Bhatia et al., 2014).  
 The results of this meta-analysis demonstrate that both epidemiological and 
clinical studies suggest an association between psoriasis, celiac disease, and celiac 
disease markers.  The authors conclude that health care providers should screen their 
patients with psoriasis for symptoms of celiac disease, including diarrhea, flatulence, 
fatigue and history of iron-deficiency anemia.  Positive findings should flag providers to 
then run serological tests for celiac associated antibodies (Bhatia et al., 2014).   
Association of Psoriasis with Other Autoimmune Diseases.  Wu, Nguyen, 
Poon and Herrinton (2012) conducted a retrospective cohort study in order to examine 
the association between psoriasis and 21 autoimmune diseases that share common 
pathogenetic mechanisms, including celiac disease, Crohn’s disease and RA.  The authors 
also looked closely at patients with both psoriasis and psoriatic arthritis, hypothesizing 
that these individuals would be even more likely to have an additional autoimmune 
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disorder, compared to individuals with psoriasis alone (Wu, Nguyen, Poon & Herrinton, 
2012).  This study has been rated a 2+.   
The study population was formed from patients who were members of the Kaiser 
Permanente Southern California (KPSC) health plan from January 1, 2004 to February 
28, 2011.   Inclusion criteria were as follows:  patients of age 0 to 100 years, with at least 
one year of enrollment during the designated timeframe, and two or more inpatient or 
outpatient diagnoses codes for psoriatic disease (International Classification of Diseases, 
Ninth Revision (ICD-9), code 696.0-1), two codes for psoriasis only (ICD-9 code 696.1), 
2 codes for psoriatic arthritis (ICD-9 code 696.0), or codes for both psoriasis and 
psoriatic arthritis (one code each of 696.1 and 696.0) (Wu et al., 2012).    The comparison 
group was formed by randomly selecting individuals without psoriatic disease from 
KPSC at a ratio of five to one, and matching these individuals to the cohort by gender, 
year of birth (± one year) and length of enrollment (± one year) from the first date.  
25,341 patients with psoriatic disease were ultimately matched with 126,705 control 
subjects (Wu et al., 2012).     
Data was collected from the clinical and administrative databases of KPSC, to 
include patient demographics, inpatient/outpatient visits, and additional diagnoses (the 
outcome variables) for the 21 autoimmune diseases included in this study (Wu et al., 
2012).   Statistical analysis was conducted using SAS Enterprise Guide, version 4.3.  The 
association between each autoimmune disease (the outcomes) and psoriasis (the 
exposure) was calculated using X2 test.  Conditional logistic regression was performed to 
the compare the risk of autoimmune disease between psoriatic disease and the matched 
control subjects (Wu et al., 2012).    
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Psoriasis was positively associated with 17 of the 21 studied AI diseases, with 14 
of these associations being statistically significant (Wu et al., 2012).  The strongest 
association was with RA (OR=3.6; 95% CI 3.4-3.9).  Patients with psoriasis were 3.6 
times more likely to have RA, as compared to persons without psoriasis.  Celiac disease 
was the third strongest association (OR=2.3; 95% CI 1.6-3.2), and Crohn’s disease was 
the fifth strongest association (OR=1.8; 95% CI 1.5-2.2) (Wu et al., 2012).   Combining 
patients with both psoriasis and psoriatic arthritis demonstrated a significantly increased 
OR with most autoimmune diseases.  And, individuals with psoriatic disease were more 
likely to have at least two (OR=1.6; 95% CI 1.5-1.7) or three (OR=1.9; 95% CI 1.6-2.4) 
immune-mediated diseases compared to persons without psoriatic disease (Wu et al., 
2012).  These findings suggest that patients with psoriasis are more likely than control 
subjects to be given the diagnosis of an additional autoimmune disease.  The authors 
conclude their study by recommending that the evaluation of patients with psoriasis for 
other autoimmune diseases may be warranted as part of their health care (Wu et al., 
2012). 
Some of the limitations that are characteristic to cohort studies may have been 
present in this study.  First, diagnostic information was culled from databases and prior 
diagnostic codes, neither of which were validatable (possible information bias).  Second, 
due to their medical issues, the patients with psoriasis may have had more frequent 
contact with the health care system resulting in a greater opportunity to record associated 
diseases, as compared to the control group.  On this point, and in defense of the study, it 
was conducted over a sufficient length of time that providers should have had ample 
opportunity to recognize additional diagnoses, even in the cohort group who may have 
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had fewer health care management needs.  Third, a lack of data regarding possible 
confounders did not allow the authors to make adjustments in relation to the outcomes.  
Finally, another limitation to this study is that is was restricted to the geographic location 
of southern California.   
Psoriasis and Co-morbidities, Analysis of Health Insurance Data in 
Germany.  Augustin, Reich, Glaeske, Schaefer and Radtke (2010) conducted a 
retrospective cohort study using a large sample of German health insurance information.  
The authors’ objective was to evaluate the prevalence of co-morbidities in patients with 
psoriasis, particularly those related to metabolic syndrome.  Given the existing evidence 
that points to a relationship between psoriasis and other IMIDs, the authors also evaluated 
the association between psoriasis and RA and Crohn’s disease (Augustin, Reich, Glaeske, 
Schaefer & Radtke, 2010).  This study has been rated a 2+. 
Patients with psoriasis were first identified from a pool of 1.3 million individuals 
who were insured by a German nationwide statutory health insurance during the year 
2005.  Individuals were counted as cases if they had at least one visit to a healthcare 
provider documented with the World Health Organization (WHO) ICD-10 codes marking 
psoriasis (L40).  Individuals from this dataset without a diagnosis for psoriasis were 
marked as controls.  In total, 33,981 individuals were identified for having psoriasis and 
1,310,090 individuals without psoriasis served as the controls (Augustin et al., 2010).   
The Pharmafacts Research Institute, located in Berlin, Germany, performed data 
analysis.  Prevalences were calculated for co-morbidities of interest and the prevalence 
ratio was determined by comparing the prevalence rate of the psoriatic group to the non-
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psoriatic group.  Corresponding confidence intervals were computed by a general method 
based on constant X2 boundaries (Augustin et al., 2010). 
Individuals with psoriasis showed increased rates of co-morbidities compared to 
individuals without psoriasis (Augustin et al., 2010).  Metabolic syndrome was more 
frequently diagnosed in those with psoriasis (PR=2.86; 95% CI 2.21-3.71).  Moreover, 
the medical conditions that collectively contribute to metabolic syndrome were also 
significantly more common among patients with psoriasis on an individual level:  
diabetes mellitus (PR=2.02; 95% CI 1.96-2.08); hyperlipidemia (PR=1.75; 95% CI 1.72-
1.78); arterial hypertension (PR=1.73; 95% CI1.71-1.76); and obesity (PR=1.72; 95% CI 
1.68-1.76) (Augustin et al., 2010).   
While not of direct interest to this IMID project, the aforementioned conditions 
provide additional context when considering the prevalence rates that Augustin et al. 
(2010) calculated for RA (PR=3.84; 95% CI 3.43-4.31) and Crohn’s disease (PR=2.06; 
95% CI 1.84-2.31) among patients with psoriasis.  Rheumatoid arthritis and Crohn’s 
disease ranked first and third in prevalence, respectively, among all the co-morbidities 
studied.  This is noteworthy when one considers that approximately 34% of adults in the 
United States could be characterized as having metabolic syndrome (CDC, 2009), the 
second highest prevalent co-morbidity from this study.  Whereas health care providers 
routinely screen for the components of metabolic syndrome (hypertension, cholesterol 
levels, BMI and diabetes), RA and Crohn’s disease are not routinely screened for, 
although perhaps they should be, especially in patients with psoriasis.  Augustin et al. 
(2010) do not directly make this recommendation, however, the authors make two 
significant statements:  (1) the results of this study strongly support the association of 
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psoriasis and systemic chronic inflammatory diseases and (2) these findings should 
influence the healthcare management of patients with psoriasis by clinicians.   
The limitations of this study are similar to those previously mentioned in the 
review of the Wu et al. (2012) study; possible information bias, lack of clinical data 
allowing for the adjustment of outcomes as related to potential confounders (smoking 
status or psychosocial factor), possible increased health care visits for psoriatic patients 
versus the controls, and geographic area. 
Psoriasis and Co-morbidities, Analysis of a National Database in Taiwan.  
Tsai et al. (2011) conducted a study similar to Augustin et al. (2010).  A retrospective 
cohort study (with controls) was performed using the Taiwan National Health Insurance 
Research Database (NHIRD) during 2006.  The authors’ aim was to study the prevalence 
of comorbidities in patients with psoriasis.  This large database, representing 99% of the 
total Taiwanese population, was utilized with the hopes of capturing less commonly 
assessed disease associations such as with the autoimmune disorders rheumatoid arthritis 
and Crohn’s disease (Tsai et al., 2011).  This study has been rated a 2+. 
The NHIRD covers all benefit claims for approximately 22 million Taiwanese 
enrollees, and was established in 1995 by the National Health Research Institute and the 
National Health Insurance Bureau for the promotion of research on present and emerging 
medical issues in Taiwan (Tsai et al., 2011).   This database was utilized to identify 
patients with at least one outpatient visit or admission claim with an ICD-9 diagnosis for 
psoriatic arthropathy (696.0) or psoriasis (696.1), resulting in a sample of 51,800 cases.  
75.08% of the patients were identified at departments of dermatology, 3.42% at 
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departments of immunology/rheumatology, and 21.51% from “other,” non-specified 
departments (Tsai et al., 2011).   
The psoriasis cases were then further classified by severity.  Individuals who had 
received any systemic therapy or phototherapy in 2006 were designated as moderate to 
severe (sPsO, n=9,063), while those who had not were designated as mild psoriasis 
(mPsO, n=36,252).  The control group (n=207,200) was established by identifying 
patients without diagnoses for either psoriatic arthropathy or psoriasis, and matched at a 
4:1 ratio based on age, gender and residential area (Tsai et al, 2011).   Co-morbidities 
were defined based on at least three claims for an outpatient visit or one hospitalization 
with a principal/secondary diagnosis within one year of the index date, 2006 (Tsai et al., 
2011).   
The authors calculated prevalence associated with psoriasis and co-morbidities 
between cases and controls using relative risk (RRs) and 95% confidence intervals (CI) 
based upon a Cox proportional regression model (Tsai et al., 2011).  The authors found 
that patients with psoriasis had a total increased risk for depression (RR=1.50; 95% CI 
1.39-1.61, p-value >.0001), hypertriglyceridemia (RR=1.61; 95% CI 1.54-1.68, p-value 
>.0001), hypertension (RR=1.51; 95% CI 1.47-1.56, p-value >.0001), diabetes (RR=1.64; 
95% CI 1.58-1.70, p-value >.0001), cardiovascular disease (RR=1.32; 95% CI 1.26-1.37, 
p-value >.0001) and malignancies of the digestive organs and peritoneum (RR=1.57; 
95% CI 1.41-1.74, p-value >.0001).  
Interestingly, in this study patients with moderate to severe psoriasis were found 
to have 10.25 times the risk for RA (95% CI 8.20-12.81), and patients with mild psoriasis 
were found to have 1.56 the risk for RA (95% CI 1.33-1.83) compared to patients without 
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psoriasis.  The total risk for RA among all patients with psoriasis was calculated to be 
3.02 times that for non-psoriatic patients (95% CI 2.68-3.41).  When compared to the co-
morbidities listed in the previous paragraph, RA by far demonstrates the highest risk 
among patients with psoriasis.  These results echo the findings published in the Augustin 
et al. (2010) study.   
Finally, the percentage of psoriatic patients with Crohn’s disease was actually 
lower in this study as compared to patients without psoriasis, although the authors state 
that this lower percentage did not show statistical significance.   Tsai et al. (2011) 
postulate that the difference in association between psoriasis and Crohn’s disease may 
relate to ethnic differences in shared genetic susceptibility loci or, alternatively, in the 
presence of disease protection loci.     
The relevance of these findings is significant, particularly with regards to patients 
with moderate to severe psoriatic disease.  Tsai et al. (2011) conclude their study by 
suggesting that clinicians should take into consideration the association of co-morbidities 
when evaluating the potential burdens of psoriatic patients and designing effective health 
care management plans. 
A Comparison of Prevalence Ratios in Patients with Psoriatic Arthritis and 
Psoriasis.   Through another retrospective cohort study, Makredes, Robinson, Bala and 
Kimball (2009) investigated whether patients with psoriatic arthritis (PsA) carry a higher 
AI disease burden than patients with psoriasis (PsO) alone.  These authors utilized the 
IMS Health Integrated Administrative Claims Database (Norwalk, CT) to compare the 
prevalence of seven AI disorders among patients with PsA and PsO (Makredes, 
Robinson, Bala & Kimball, 2009).  The AI disorders were chosen based on a lack of 
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overlapping dermatologic or rheumatologic clinical manifestations to psoriasis or 
psoriatic arthritis (Makredes et al., 2009).  Crohn’s disease and inflammatory bowel 
disease were among the seven AI disorders examined.  This study has been rated a 2+. 
At the time of this study, the IMS Health Integrated Administrative Claims 
Database covered approximately 11 million individuals.  From this dataset, patients were 
selected on the basis of age greater than 18, with at least one medical service visit of any 
kind between the dates of January 1, 2001 and December 31, 2002, and indicating at least 
one ICD-9 psoriasis code (696.0-1).   25,556 individuals were identified based on these 
criteria.  These individuals were then classified into two clinical subsets, individuals with 
arthritic manifestations (PsA; ICD-9 696.0, n=3066) and those without arthritic 
manifestations (PsO; ICD-9 696.1, n=22,499).   Individuals in the PsO group were not 
allowed to also have the presence of a PsA diagnostic code (Makredes et al., 2009).       
Control groups for both subtypes were selected at a 3:1 ratio, matching for at least 
one medical encounter, age (within two years), sex, US census region, and length of 
previous medical insurance coverage.  The control subjects could not have any ICD-9 
psoriasis code in their records during the two year period of study (Makredes et al., 
2009).       
The case identification for other AI disorders required at least one medical claim 
for the ICD-9 diagnostic code of interest.  The occurrence rates for these AI diseases 
were compared among control subjects, the PsO group, and the PsA group using the 
prevalence ratio (PR) statistic.  A 95% CI was estimated with the Mantel-Haenszel test 
(Makredes et al., 2009).  The authors found statistically significant trends between 
several AI disorders and both psoriasis subtypes, with the strongest relationships 
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belonging to PsA.  Of particular interest, patients with PsO had an increased PR 
associated with Crohn’s disease (1.6; 95% CI 1.4-2.0) and inflammatory bowel disease 
(1.4; 95% CI 1.2-1.6) when compared to individuals without psoriasis.  Demonstrating an 
even stronger relationship, patients with PsA also carried an increased risk for Crohn’s 
disease (2.1; 95% CI 1.3-3.3) and inflammatory bowel disease (1.8; 95% CI 1.3-2.5).  
Based on these findings, Makredes et al. (2009) reach three conclusions. First, the 
data supports the premise that PsA and PsO are associated with the development of other 
AI diseases.  Second, patients with PsA and PsO appear to be at greater risk for GI 
diseases.  Third, these findings suggest that evaluating psoriatic patients in a prospective 
manner for other associated AI disorders may be important toward the patient’s long-term 
health outcomes (Makredes et al., 2009).   
Psoriasis, Psoriatic Arthritis and Increased Risk of Crohn’s Disease in US 
Women.   Li, Han, Chan and Qureshi (2013) performed a prospective cohort study in 
order to evaluate the association between psoriasis, psoriatic arthritis and incident UC 
and CrD among women in the US.  The authors utilized two large, ongoing prospective 
studies of US women for their assessment, the Nurses’ Health Study (NHS) and the NHS 
II (Li, Han, Chan & Qureshi, 2013).  Collectively, these two datasets provide over 30 
years of biennially updated data on diagnoses and lifestyle. This study has been rated a 
2+.   
The NHS enrolled 121,701 US female nurses aged 30-55 years in the year 1976 
after a mailed questionnaire was completed detailing medical history and lifestyle factors.  
In 1989, NHS II was established when a similar questionnaire was completed by 116,430 
US female nurses, aged 25-42 years.  The information from both cohorts has been 
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undated every two years, with a response rate exceeding 90%.   In 2005 and 2008, 
respectively, NHS and NHS II enrollees were questioned about physician-diagnosed 
psoriasis, psoriatic arthritis, and the diagnosis date.  Self-reported psoriatics were 
confirmed by using the Psoriasis Screening Tool (PST); psoriatic arthritis was confirmed 
through the PsA Screening and Evaluation (PASE) questionnaire (Li et al., 2013).   
Participants who reported a diagnosis of UC or CrD in consecutive NHS and NHS II 
responses were asked to complete a supplementary questionnaire and for permission to 
review their medical records.  Two gastroenterologists, who were blinded to exposure, 
reviewed these medical records; diagnosis for UC or CrD was confirmed if the original 
diagnosis was established through the fulfillment of standardized criteria (Li et al., 2013).    
A critical aspect of this study was confirmation that the psoriasis diagnosis preceded the 
diagnosis for either UC or CrD (Li et al., 2013). 
Statistical analysis was performed using SAS and all p-values were two tailed.  
The following calculations were made:  (1) time dependent Cox proportional hazards 
model stratified by age for the estimation of relative risks (RRs) and 95% CI; (2) 
multivariate analysis with adjustments for age, BMI, smoking, alcohol intake, physical 
activity, and use of postmenopausal, oral contraceptive, aspirin and NSAID drugs; (3) 
between-studies heterogeneity and overall association from random effects (Li et al., 
2013).    
Total number of participants in this study was 174,476 (78,211 from NHS and 
96,265 from NHS II).  2,755 women reported a diagnosis of psoriasis at baseline (1996 
for NHS and 1991 for NHS II).  An additional 512 women from NHS and 1,122 women 
from NHS II reported psoriasis over follow-up through 2005.    In NHS, there were 72 
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confirmed cases of CrD and 116 cases of UC from 1996 to 2008.  In NHS II, there were 
116 confirmed cases of CrD and 166 cases of UC from 1991 to 2007.  Li et al. (2013) 
report that women with psoriasis had an increased risk of developing CrD with a 
multivariate adjusted RRs of 4.05 (95% CI 1.75-9.38) in NHS and 3.76 (95% CI 1.82-
7.74) in NHS II.  The pooled analysis demonstrated that psoriasis was associated with a 
RR of 3.86 (95% CI 2.23-6.67) for developing CrD (Li et al., 2013).  The authors did not 
find a statistically significant increased RR for development of UC in women with 
psoriasis in either database (Li et al., 2013).   
The authors also examined the risk for CrD among women with both psoriasis 
and psoriatic arthritis.  In addition to observing a particularly high risk of CrD among 
female patients with psoriasis and psoriatic arthritis (RRpooled=6.54; 95% CI 2.07-20.65), 
Li et al. (2013) also observed a higher risk associated with longer duration and earlier 
onset of psoriasis.  Together, these findings offer additional evidence in the support of 
common underlying mechanisms between psoriasis and CrD.   Because the study was 
limited to US female healthcare workers, additional research should be conducted in 
other populations to confirm results.   
Psoriasis Associated with UC and Crohn’s Disease.  Cohen, Dreiher and 
Birkenfeld (2009) investigated the relationship between psoriasis and the components of 
inflammatory bowel disease, UC and CrD, through a case-control study that utilized the 
large medical dataset of Clalit Health Services (CHS).  The authors theorized that as both 
UC and CrD are associated with inflammation, and that both diseases are treated with and 
respond to similar medications, that these inflammatory bowel diseases may each be 
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independently associated with psoriasis (Cohen, Dreiher & Birkenfeld, 2009).  This study 
has been rated a 2+. 
Clalit Health Services is the largest healthcare provider organization in Israel, 
serving a population of approximately 3,800,000 enrollees at the time of this study.   This 
database receives continuous, real-time information from pharmaceutical, medical and 
administrative operating systems, facilitating epidemiological studies via the Clalit 
Research Institute.  Cohen et al. (2009) identified patients from this database who had at 
least one documented diagnosis for psoriasis by a CHS community provider or through 
hospital discharge diagnosis.  The authors matched the cases with controls, also from 
CHS, at a 2:1 ratio.  Patient cases numbered 12,502; cohorts without psoriasis were 
matched by sex and age, equaling 24,285 patients (Cohen et al., 2009).   The authors also 
extracted information regarding diagnoses for UC or CrD, as well as patient use of the 
following three anti-TNF-α drugs, infliximab, etanercept and adalumumab.   
Statistical analysis was performed using SPSS software, version 13.  The authors 
compared the proportion of patients with IBD between patients with and without 
psoriasis.  For categorical parameters between the groups, chi-squared tests were 
performed, while t-tests were used for comparison of continuous variables.  Logistic 
regression was then used to measure the association between psoriasis and UC and CrD 
in a multivariate analysis of variables stratified for age, gender, socioeconomic status 
(SES), and smoking status (Cohen et al., 2009).   
The prevalence of both UC and CrD was significantly increased in patients with 
psoriasis compared to those without psoriasis.  The association of UC and psoriasis 
compared with controls was statistically significant in patients 20-39 years old (OR=5.78; 
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95% CI 1.81-18.5, p-value ≤ 0.001), in male patients (OR=1.78; 95% CI 1.11-2.82, p-
value < 0.05), and in non-smokers (OR=1.99; 95% CI 1.34-2.95, p-value ≤ 0.001).  The 
multivariate analysis findings indicate that ulcerative colitis was significantly associated 
with a co-diagnosis for psoriasis (OR=1.65; 95% CI 1.15-2.33), as well as with age, sex 
and SES of the patient (Cohen et al., 2009). 
The association of CrD and psoriasis compared with controls demonstrated 
similar, but more widespread results.  For example, while UC showed statistical 
significance with patients aged 20-39 years, CrD was associated with patients in both the 
20-39 (OR=6.05; 95% CI 2.91-12.6) and 40-59 (OR=2.14; 95% CI 1.13-4.05) age 
brackets.  A significant association was also found for patients with psoriasis and CrD for 
both genders, with a higher burden on females (OR=4.60; 95% CI 2.50-8.45) versus 
males  (OR=1.66; 95% CI 1.02-2.71), as well as in smokers (OR=2.78; 95% CI 1.26-
6.16) and non-smokers (OR=2.48; 95% CI 1.61-3.80), compared to controls.  The 
multivariate analysis indicates that, likewise to UC, CrD is significantly associated with 
co-disease of psoriasis (OR=2.49; 95% CI 1.71-3.62), age, sex and SES (Cohen et al., 
2009). 
As with other epidemiological studies utilizing secondary data, the major 
limitation of this study was an inability to confirm patient diagnoses, either for psoriasis, 
CrD and UC.  Misclassification of information cannot, therefore, be completely ruled out.  
However, the authors stand by the strength of the CHS data warehouse, which sources all 
data through a universal EHR system, and capitalizes upon the expertise of Israel’s 
practitioners (Cohen et al., 2009).   In summary, the findings of this study cast additional 
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support for a significant association between psoriasis and the inflammatory bowel 
diseases.   
Psoriasis and Celiac Disease.  Three of the authors from the previous study 
Birkenfeld, Dreiher, and Cohen, collaborated with a fourth author, Weitzman (2009) to 
investigate the association between psoriasis and celiac disease.  With the exception of 
the evaluated outcome (celiac disease), this study mirrored the one previously described.  
This case-control study also utilized the large medical dataset of Clalit Health Services 
(CHS) and has been rated a 2+. 
This study included 12,502 patients with psoriasis who were greater than twenty 
years old and 24,285 patients without psoriasis who were matched on a 2:1 ratio based on 
age and sex (Birkenfeld, Dreiher, Weitzman & Cohen, 2009).   The prevalence of CD 
was greater in patients with psoriasis than in controls.  The association between psoriasis 
and CD was further evaluated by age, 20-39 years, 40-59 years and 60-110 years.  In all 
age groups, the association was significant, however the strength of the association 
decreased with increasing age.  Additionally, an association was prominent among 
women and among those of intermediate SES (Birkenfeld et al., 2009).   
There were neither significant confounding factors noted among age, sex or SES, 
nor effect modification by any covariate.   The multivariate logistic regression analysis 
revealed that psoriasis was associated with CD (OR=2.73; 95% CI 1.65-4.53, p-value < 
0.001).  The strength of the associated remained significant after controlling for age, sex 
and SES (OR=1.79; 95% CI 1.03-3.10, p-value = 0.039).  
The authors conclude that healthcare providers should be aware of the possible 
association between psoriasis and CD.  Active screening for CD may lead to a diagnosis 
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of latent CD in patients with other autoimmune diseases, particularly in those with 
psoriasis (Birkenfeld et al., 2009). 
Serology of Celiac Disease in Psoriasis.   Damasiewicz-Bodzek and 
Wielkoszynski (2008) investigated whether patients with psoriasis also had increased 
levels of CD-associated antibodies compared to healthy controls, implicating gluten 
intolerance.   The authors measured titres of IgA and IgG antibodies against tissue 
transglutaminse from guinea pig liver (a-GP-tTG), of IgA antibodies against human 
recombinant tissue transglutaminase (a-h-r-tTG IgA), of anti-gliadin antibodies (AGA 
IgA and AGA IgG), as well as anti-endomysial antibodies for IgA (IgEmA) in patients 
with and without psoriasis.  The aim of this study was to demonstrate whether there is an 
increase in the frequency of those markers of CD in patients with psoriasis 
(Damasiewicz-Bodzek & Wielkoszynski, 2008).  This cross sectional study has been 
rated 3.   
 The cases were identified based on hospital admission for intensified psoriatic 
skin lesions in the Upper Silesia (Poland) region.  A total of 67 patients were included; 27 
females and 40 males whose mean PASI score measured 25.9 ± 14.9.  Patients with 
psoriatic arthritis and other diseases were excluded from the study.  Controls without 
psoriasis were matched for sex and age.  Patients with a family history for either psoriasis 
or celiac disease were excluded from the control group.  The study commenced prior to 
any anti-psoriasis treatment was started, and all cases and controls were on gluten-
containing diets.  Blood samples were collected from both groups, following an overnight 
fast (Damasiewicz-Bodzek & Wielkoszynski, 2008).      
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 Approximately 6% of psoriatic patients screened positive for four serologic 
markers, while 28.1% had three serologic markers positive, and 17.7% had two serologic 
markers positive.  The authors proceeded to test the data in triplicate (Kolmogorov-
Smirnov, U Mann-Whitney and Wald-Wolfowitz’s) revealing that patients with psoriasis 
have statistically significant higher mean levels of antibodies against tissue 
transglutaminase from guinea pig liver (a-GP-tTG) for both IgA (p <0.001, P=0.000000 
and p=0.000006, respectively) and IgG (p < 0.001, p=0.000001, and p=0.01) than do 
patients without psoriasis.   Furthermore, in 46% of the cases for IgG, and as much as 
66% of the IgA cases, titres of antibodies were higher than the 90th percentile of the 
control values.  Patients with psoriasis also had higher mean levels of IgA antibodies 
against the human recombinant tissue transglutaminase (p < 0.001, P = 0.036 and 
p=0.002); 54% of the cases were higher than the 90th percentile of the control values.  
The titres of antibodies against gliadin between psoriatics and controls were increased at 
statistically significant levels for IgA (p < 0.001, p = 0.000000 and p = 0.0005), but not 
for IgG (p > 0.01, p = 0.75, and p = 0.244).   And no anti-endomysial antibodies for IgA 
were found in any serum, either cases or controls. (Damasiewicz-Bodzek & 
Wielkoszynski, 2008).      
 The authors also used the Spearman rank correlation to test the association 
between the examined antibodies and the PASI score.  Concentrations of a-h-r-tTg IgA 
positively correlated with concentrations of a-GP-tTG IgA, a GP-tTg IgG and AGA IgA.  
Concentrations of a-h-r-tTG IgA, a-GP-tTG IgA and AGA IgA also positively correlated 
with PASI (Damasiewicz-Bodzek & Wielkoszynski, 2008).    Given the widely accepted 
use of these serologic antibody tests to diagnose celiac disease, these results suggest that 
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there is an association between psoriasis and asymptomatic celiac disease/gluten 
intolerance (Damasiewicz-Bodzek & Wielkoszynski, 2008).     
 Early Detection of Crohn’s Disease in Psoriasis.  Radtke et al. (2015) published 
the results of a German interdisciplinary partnership whose objective was to develop 
screening algorithms for dermatologists for twelve different comorbidities in patients 
with psoriasis, including chronic inflammatory bowel disease.  This effort stemmed from 
a national survey on psoriasis care in 2005, which indicated deficits in care for those with 
psoriasis in Germany.  As a result, the German “National Healthcare Goals in Psoriasis 
2010-2015” defined early detection of comorbidities in psoriatic patients as a nationwide 
goal of dermatological care (Radtke et al., 2015).  At the 2010 Healthcare Research 
Conference, the establishment of a methodological basis for the implementation of this 
health care goal was tasked to a working group of the conference and confirmed by the 
German Society of Dermatology (DDG) and the Professional Association of German 
Dermatologists (BVDD).  The goal of this work was to develop descriptive and practical 
screening algorithms, thereby providing dermatologists with the decision-making tools 
required for early diagnosis of comorbidities (Radtke et al., 2015).   This consensus paper 
would be considered expert opinion, and as such this study has been rated a 4.   
The task was approached from a three-stage process. First, a national consensus 
conference on psoriasis established a definition for the requirements, areas of application, 
conception, and methodology of an agreed screening algorithm (Radkte et al., 2015).   
Second, a literature search was conducted to investigate the most relevant comorbidities 
associated with psoriasis, as well as possible screening approaches.  More than 2,000 
publications were included in the appraisal and evidence for the use of screening 
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parameters for the individual comorbidities was compiled (Radtke et al., 2015).  Finally, 
an interdisciplinary group of the National Healthcare Conference evaluated the 
algorithms according to content-related, methodological, and formal characteristics, as 
well as practicability.  The algorithms were then adopted through a Delphi consensus 
process (Radtke et al., 2015).   
Since dermatologists in Germany are the most frequently consulted provider for 
patients with new onset psoriasis, it was considered imperative that these providers 
facilitate early detection of associated comorbidities.  The twelve comorbidities chosen 
for screening in patients with psoriasis included arterial hypertension, dyslipidemia, 
obesity, diabetes mellitus, metabolic syndrome, nonalcoholic steatohepatitis, depression, 
nicotine abuse, alcohol abuse, psoriatic arthritis, malignant lymphoma and chronic 
inflammatory bowel disease (Radtke et al., 2015).  The following target parameters for 
screening were identified for IBD. 
Table 2.2  Screening Parameters for IBD 
 
Chronic diarrhea (> 3 bowel movements 
per day and > 4 weeks) and ≥ 1 of the 
following symptoms: 
Blood in stool 
Pain or bleeding during intestinal 
peristalsis 
Painful defecation (DD: differentiation 
from anal fissure, hemorrhoids) 
Abdominal pain especially in the right 
lower abdomen 
Pyoderma gangrenosum, erythema 
nodosum, oral aphthae 
Temperature > 37.8 °C (100 °F) during the 
past 7 days 
Weight loss 
Anal fistula, anal fissures, or perirectal 
abscesses or other fistulas (e.g. entero-
vesical fistula) 
Ocular involvement: uveitis or iritis 
Arthritis or arthralgia 
(Radtke et al., 2015) 
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The recommended interval for follow-up examinations for individuals with mild 
psoriasis is every 12 months, and every 6 months for individuals with severe psoriasis 
(Radtke et al., 2015).   The collaborative efforts of DDG and BVDD underscore the 
importance of primary prevention and health promotion in at risk groups, particularly in 
those with psoriasis.     
2.6 Synthesis of Findings 
 Of the fourteen articles reviewed for this evidence-based project, ten investigated 
the association of psoriasis with Crohn’s disease, seven with celiac disease, and four with 
rheumatoid arthritis.  Among the four genetic studies with varying research 
methodologies, a pattern emerges that lends support for an association between psoriasis 
and the three AI diseases under investigation.  Tsoi et al. (2013) demonstrated that 39 
psoriasis susceptibility loci are known today, ten of which overlap with Crohn’s disease, 
nine with celiac disease, and five with rheumatoid arthritis.   And, a significantly 
increased multiple AI disease risk was found to be associated with the CD226 Gly307Ser 
t allele rs763361, a gene that has been reported to be associated with psoriasis, celiac 
disease, and rheumatoid arthritis (Qui et al., 2013).  The Wolf et al. (2008) study implies 
that three Crohn’s disease SNPs are significantly associated with psoriasis.  Finally, the 
results of Einarsdottir’s et al. (2009) study suggest that there is an association of IL23R 
with Crohn’s disease, psoriasis and celiac disease.   
 A similar pattern appears within the population based studies.  Among those 
focusing on psoriasis and celiac disease, two studies demonstrate a positive association 
between psoriasis and celiac disease (Birkenfeld et al., 2009; Wu et al., 2012), while two 
more also demonstrate that patients with psoriasis tend to exhibit the presence of 
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serological markers associated with celiac disease (Bhatia et al., 2014; Damasiewicz-
Bodzek & Wielkoszynski, 2008).  Further, evidence suggests that a GFD, typically 
prescribed to patients with celiac disease, may lead to resolution or improvement of 
psoriatic lesions (Bhatia et al., 2014).   
 Six population-based studies investigated the association between psoriasis and 
Crohn’s disease.  With the exception of one study (Tsai et al., 2011), the other five 
studies showed statistically significant associations between the two AI diseases 
(Augustin et al., 2010; Cohen et al., 2009; Li et al., 2013; Makredes et al., 2009; Wu et 
al., 2012).   It is also very compelling that dermatologists in Germany have 
acknowledged the relationship between psoriasis and IBD, recommending that providers 
screen annually for IBD in moderate cases and bi-annually in severe cases of psoriasis, in 
order to promote best patient outcomes (Radtke et al., 2015).  
 With respect to psoriasis and rheumatoid arthritis, three population-based studies 
highlight the relationship between these two AI diseases.  Wu et al. (2012) found that 
among 21 different AI disorders, RA held the strongest statistically significant 
association with psoriasis.  The Tsai et al. (2011) study found that the total risk for RA 
among all patients with psoriasis was calculated to be 3.02 times that for non-psoriatic 
patients.  And, individuals with psoriasis showed increased rates of RA compared to 
individuals without psoriasis in the Augustin et al. (2010) study.   
2.7 Summary 
 While it is clear that the autoimmune puzzle is by no means complete, requiring 
substantial and robust future research efforts, healthcare providers may be able to take 
into consideration and utilize the information presently available, which is as follows.  
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One, autoimmune disorders can take years to diagnose, primarily because symptoms may 
present vaguely and also due to healthcare provider knowledge deficits about AI diseases 
in general, and how they relate to one another.  Two, earlier detection of autoimmune 
diseases and initiation of treatment may improve patients’ long-term outcomes.  Three, 
individuals with one autoimmune disorder are more likely than the general population to 
have one or more other AI diseases.  Four, the most prevalent AI disease is psoriasis.  
Five, psoriasis belongs to a subset of AI diseases called IMIDs, which includes celiac 
disease, rheumatoid arthritis and Crohn’s disease.  There is a genetic relationship among 
these diseases.  Six, individuals with psoriasis seem to have an increased risk of also 





 Research indicates that individuals with psoriasis may be predisposed to the three 
IMIDs of interest to this study, celiac disease, rheumatoid arthritis and Crohn’s disease.  
The literature also suggests that health care providers would be prudent to evaluate 
psoriatic patients in a prospective manner for these AI disorders in order to improve the 
patient’s long-term health outcomes.  
The purpose of this project is to conduct a substantive review of the literature and 
conduct screening of primary care patients with psoriasis to determine early detection of 
celiac disease, rheumatoid arthritis, and Crohn’s disease. The objective of this quality 
improvement project is to administer a patient questionnaire to adult patients aged 18 
years and greater with psoriasis, screening for signs and symptoms of celiac disease, 
rheumatoid arthritis and Crohn’s disease. This quality improvement project was guided 
by evidence provided by the literature search and synthesis, the methods based on the 
Iowa Model of Evidence-Based Practice.  The Iowa Model provided a guideline to 
decrease barriers while instilling confidence in the new patient questionnaire.  This 
chapter will present the methods for conducting the project.  A detailed process is 
outlined for implementing the project, including a time frame, intervention, and data 
management.   
		 68	
3.2 Design   
The project will implore a retrospective (chart review), one test design to 
determine if the patient with psoriasis has been screened as noted by the provider 
documentation. The provider will make a referral for further diagnostic testing or to a 
specialist based on the patient questionnaire algorithm, which will be noted in the 
provider’s documentation.    
3.3 Instrument 
To date, no individual screening tools have yet been validated as having sufficient 
predictive ability for celiac disease, rheumatoid arthritis or Crohn’s disease.  Diagnosis 
for these AI diseases relies upon a combination of patient history, physical examination, 
laboratory tests, imaging studies and biopsy (Pincus, Yazici & Sokka, 2009). Current 
diagnostic algorithms are founded on the if/than approach: if these symptoms exist, and if 
positive serologies or scans/biopsy are present, than we can conclude diagnosis.   The 
path to diagnosis still begins with a provider’s strong suspicion of disease.   
For groups that have been identified to be at higher risk than the general 
population for development of these AI diseases, including patients with psoriasis, 
practitioners’ must have a simple tool that kindles suspicion, opens discussion, and 
facilitates investigation at the earliest signs of possible disease.  Patient questionnaires 
used in clinical practice are effective toward collecting patient information, guiding 
management, documenting change in status, assessing outcomes, and improving the 
quality of care (McCollum & Pincus, 2009).  Therefore, an immune-related patient 
questionnaire and referral algorithm have been developed based on the current 
understanding of signs and symptoms for these AI diseases.   
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 According to the guidelines developed by both the American College of 
Gastroenterology (Rubio-Tapia et al., 2013) and the British Society of Gastroenterology 
(Ludvigsson et al., 2014), any patient with signs or symptoms of CD should undergo 
testing.  These include the following:  chronic or recurrent diarrhea, weight loss, 
abdominal pain after eating, abdominal distention or bloating after eating, history of 
Irritable Bowel Syndrome (IBS), anemia, vitamin D deficiency, or elevated liver 
enzymes.  The aforementioned guidelines, as well as those developed by the American 
Gastroenterological Association (AGA) Institute (Kagnoff, 2006), further indicate that 
symptomatic, first-degree relatives with celiac disease are at a higher risk for CD than 
those in the general population, with a prevalence of approximately 10%, and should be 
tested for CD. 
 According to the American College of Gastroenterology (Lichtenstein et al., 
2009) and Laass, Roggenbuck and Conrad (2014) with the Institute of Immunology, 
patients should be suspected for Crohn’s disease with the following symptomology:  
chronic or recurrent diarrhea, weight loss, abdominal pain after eating, painful bowel 
movements, blood in stool, or fever.  The European Crohn’s and Colitis Organization 
(Van Assche et al., 2009) supports testing in symptomatic patients who have previously 
been told they have IBS, or have a history of anemia, vitamin D defiency, or elevated 
liver enzymes.   All authors agree that family history is key, due to the fact that first-
degree relatives of patients with Crohn’s disease have a 10-15 fold risk for also having 
Crohn’s disease.  Symptomatic patients with family history should be investigated for 
Crohn’s (Laass et al., 2014; Lichtenstein et al., 2009; Van Assche et al., 2009).  
 Finally, recommendations from the National Guideline Clearinghouse (2012) and 
		 70	
the ACR/EULAR classification criteria (Cohen & Emery, 2010) guided the questions 
related to rheumatoid arthritis.  Patient with the following signs and symptoms should be 
considered for RA, including morning stiffing for greater than 30 minutes for more than 6 
weeks, joint/muscle pain on a daily basis for more than 6 weeks, tender/swollen joints on 
a daily basis for more than 6 weeks, tingling in hands/feet on daily basis for more than 6 
weeks, plus weakness/fatigue for more than 6 weeks. 
The purpose of this patient questionnaire is two-fold:  (1) to improve and 
streamline the screening process for health care providers for celiac disease, Crohn’s 
disease and rheumatoid arthritis among patients with psoriasis, and (2) to elicit immune-
related information from the client that might otherwise be overlooked, decreasing the lag 
time between symptom onset and diagnosis.  The purpose of the referral algorithm is to 
help inform provider clinical decision-making steps based on patient questionnaire 
responses.  As such, the DNP project author developed a patient questionnaire (See 
Appendix D) and referral algorithms (See Appendices E, F and G) based on existing 
evidence and guidelines for care.  Neither the patient questionnaire, nor the algorithms, 
has been tested for reliability or validity.   
The questionnaire includes two demographic questions (age and gender), one 
question regarding family history for celiac disease, Crohn’s disease, and rheumatoid 
arthritis, plus sixteen primary questions, which focus on the signs and symptoms of celiac 
disease, Crohn’s disease, and rheumatoid arthritis.  Seven of the questions pertain to both 
celiac disease and Crohn’s disease, as symptoms can be comparable between these two 
AI diseases.  Three questions are specific to Crohn’s disease, one specific to celiac 
disease, and a total of five questions specific to rheumatoid arthritis. 
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The primary questions are dichotomous, requesting a simple “yes” or “no” answer 
(0 designates “no” and 1 designates “yes” for each framed question).  Eight of these 
primary questions are conditional; if the patient provides a “yes” response, then the 
patient is directed to answer subsequent questions.  
Three algorithms for referral have also been developed, one each for celiac 
disease (see Appendix E), Crohn’s disease (See Appendix F), and rheumatoid arthritis 
(See Appendix G).  The algorithms take into consideration the patient responses to the 
questionnaire and assist the provider’s clinical decision-making regarding whether or not 
referral for additional specialty care and work up is merited. 
3.4 Unit of analysis  
The first unit of analysis is the patient questionnaire, which will be presented in 
descriptive statistics (frequency tables).   The second unit of analysis is the provider’s 
documentation of the patient questionnaire and subsequent referral, if indicated based on 
the questionnaire.		 
Data will be collated using a 2 x 2 table in which the two possible outcomes 
include whether the patient questionnaire was administered/not administered, and 
whether a referral was made/not made to a specialist for additional work-up.  The 
outcome evaluation will determine if the patient questionnaire has facilitated possible 
identification of co-autoimmunity (celiac disease, Crohn’s disease, and/or rheumatoid 
arthritis) in these psoriatic patients.   
Additionally, the information provided by the patient via the patient questionnaire 
will be entered in an Excel spreadsheet, one row per patient.  The excel database will be 
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used to calculate the prevalence of celiac disease, rheumatoid arthritis, and Crohn’s 
disease symptoms among the total number (N) of psoriatic patients seen in the practice. 
3.5 The Setting 
 The administration of the patient questionnaire will take place on location at a 
private dermatology practice in Springfield, Virginia.  The provider, referred to as “MD 
One,” is board certified in dermatology and dermatopathology, specializing in the 
diagnosis and treatment of medical, surgical and cosmetic conditions of the skin, hair and 
nails.  Practicing since 1973, MD One serves a racially diverse, urban population in the 
greater Northern Virginia area (48.7% Caucasian, 9.0% AA, 24.3% Asian, 25.5% 
Hispanic and 7.5% other).  MD One accepts private insurance through Aetna, Blue Cross 
Blue Shield, Cigna, as well as Medicare, but not Medicaid.  The lack of current protocol 
at this practice for screening patients with psoriasis for celiac disease, rheumatoid 
arthritis and Crohn’s disease has created an opportunity for a quality improvement 
project.    
3.6 Sample 
Inclusion criteria will consist of patients aged 18 years or greater, who are able to 
speak, read and comprehend English, with a current diagnosis for psoriasis.  Current 
diagnosis for psoriasis refers to existing patients being treated by MD One for psoriasis, 
as well as new referrals from primary care providers for additional psoriasis treatment.  
Furthermore, self-referred patients may also be included if a new psoriasis diagnosis 
occurs at the first visit with MD One.  Approximately thirty patients are targeted for the 
sample project.   
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3.7 Description of intervention  
Staff Training.  The two Patient Service Representatives (PSRs) at the 
dermatology practice are the initial point-of-contact for all patients and visitors.  
Responsibilities include, but are not limited to, greeting patients and visitors, assisting 
patients with appointment check-ins, obtaining information from new and established 
patients, accurate medical record entry, scheduling appointments, and answering 
telephones.  The PSRs will be critical to the implementation of the quality improvement 
project, as they will be responsible for identification of potential patients with psoriasis 
and with dissemination of the patient questionnaire.  Therefore, the author will meet with 
both PSRs on the afternoon of Friday, June 9, 2017 on-site at the practice during “down” 
time, after patient appointments have finished, typically around 12:30pm.   
The project objective, an increased understanding of co-autoimmunity among the 
psoriatic patients at the practice, as well as the supporting research, will be shared with 
the PSRs in order to promote an understanding of the project and secure buy-in from 
these participants.  Additionally, the author will demonstrate respect for the PSRs, which 
will encourage staff support.   PSRs will be provided with every opportunity to voice 
concern or questions over the questionnaire process.   PSRs will also be asked for their 
input on how to best streamline the process based on their understanding of clinic flow; 
consideration will be given to their suggestions for simplifying the overall process and 
this will promote ownership of project with PSRs. 
Following the project introduction, the questionnaire will be reviewed, and 
instruction will be given regarding the protocol for implementation of the questionnaire.  
PSRs will provide the questionnaires to adult patients aged 18 and greater that have an 
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ICD-9 diagnosis code of 696 (psoriasis and similar disorders) or ICD-10 diagnosis code 
of L40.0-L40.5 from a previous clinic visit at their check-in. This information will be 
determined from the practice’s scheduling and billing software, MacPractice, at the 
beginning of the day before the first appointment has arrived and reiterated during the 
staff’s morning “huddle.”  The MacPractice Management system allows the user to run 
reports on existing patients by diagnosis code.  For newly referred patients or self-
referred patients, the PSRs will review the reason for the patient’s appointment, via 
scheduling software notes and intake form.  If it is not apparent why the new patient 
requires dermatological expertise, the patient will simply be asked why they are being 
seen upon their arrival.   
If the previously stated qualifications are satisfied, the PSR will retrieve a blank 
questionnaire from a to-be-determined storage area, and give to the patient to fill out in 
the lobby prior to their appointment.   The PSR will collect the completed form from the 
patient and paper clip, content-side down, to the front of the patient’s chart for MD One 
to review prior to their appointment. 
MD One Training.  MD One’s buy-in is critical to the success of project 
implementation.  As the principal provider, the project intervention could potentially fail 
without his ongoing support for the duration of this project.  Therefore, MD One and the 
author project will meet Friday, June 9, 2017 in order to discuss overall project 
objectives, the foundations on which the project is based, and MD One’s involvement.    
Research findings that support the co-existence of psoriasis and celiac disease, 
rheumatoid arthritis, and Crohn’s disease will be presented to MD One. The information 
will be presented in the form of a bulleted handout during a face-to-face meeting, 
		 75	
providing MD One with the opportunity to ask questions and address any questions or 
concerns.  Additionally, the patient questionnaire and referral algorithms will be 
reviewed to ensure understanding of which symptoms will prompt additional referral 
needs.  A project outline will also be provided defining milestones and responsibilities, 
project implementation, and project completion.   
First and foremost, MD One’s primary responsibility is to review the completed 
patient questionnaire, noting pertinent positives.  It is important to note that this 
questionnaire has been designed to be simple and quick to fill-out by the patient, 
highlight potential co-autoimmune burdens, and facilitate conversation; however, it is not 
exhaustive, nor a replacement for additional medical history, physical exam, or testing.  
Therefore, when key indicators suggest potential symptomology for celiac disease, 
rheumatoid arthritis and/or Crohn’s disease, MD One will also review the referral 
algorithms to determine if the patient is a candidate for referral to a gastroenterologist or 
rheumatologist.  If the patient meets the criteria for referral, MD One will ask the PSR to 
coordinate the referral.   
Although scheduling and billing for this practice are electronic, MD One uses 
paper charting to document patient history, systems review, assessment and treatment 
plans.  For the purposes of this quality improvement project, MD One will also document 
in the paper chart that the patient has been screened via patient questionnaire and if 
referral was coordinated.  The screening questionnaire will remain in the medical chart, 
becoming a part of the patient’s permanent record.  Post visit, MD One will place the 
patient chart in a discharge bin for filing by the end of the day.   
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Project Implementation.  The implementation of the patient questionnaire will 
span a total of two weeks, five workdays per week, Monday through Friday.  The ideal 
timeframe for project execution is June 12, 2017 through June 23, 2017.   
Chart Review.  The project author will review all charts placed in the discharge 
bin throughout the day on a daily basis, so as not to disrupt the office’s daily rhythm and 
current practices.  Each chart reviewed will be recorded first, on the “Coded Identifier 
List” form (See Appendix H) and second, on the “Chart Review Data Collection Form” 
(See Appendix I).  The author will also transcribe data from completed screening 
questionnaires to the “Screening Questionnaire Data Collection Form” (See Appendix J).  
Table 3.1 indicates the timeframe for project implementation and the data collection 
process.  
Table 3.1  Time Intervals for Quality Improvement Project 
 
Activity  Timeframe  
 
Obtain IRB approval 
 
June 6, 2017 (See Appendix L) 
MD One Training 
Patient Service Representatives Training 
June 9, 2017 
Implement Patient Questionnaire June 12, 2017 through June 23, 2017 
Data Collection and Retrieval On a daily basis during the two weeks 
of project implementation  
3.8 Data Management and Analysis Methods  
As previously mentioned, three forms will be completed during the chart review:  
the coded identifier list, the chart review collection form, and the screening questionnaire 
collection form.  This data will be input into an encrypted and also password-protected 
excel file, which will be stored on a password-protected laptop, known only by the 
author.   
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The objective of the coded identifier list is to create a simple log, which will 
provide a method for a) tracking charts reviewed, ensuring that there is no duplication of 
data, and b) de-identifying participants through the assignment of a subject ID number, 
which will then be used in the two data collection forms.  The columns included in this 
form are patient name, chart number, visit date, and subject ID number.  The subject ID 
numbers will begin with “1” and run consecutively in ascending order.  This subject 
number will be transferred to the chart review collection form, and as appropriate the 
screening questionnaire collection form.  No patient identifiers will be collected that can 
be traced back to the patients’ charts. 
The chart review collection form will record the subject ID number, and if the 
patient has psoriasis (yes/no).  If the patient was not being seen for psoriasis management 
or does not have a history of psoriasis, the chart review will be completed on that patient.  
If the patient does fulfill the psoriasis requirements, than the following components will 
also be reviewed: if the questionnaire was completed (yes/no), if the provider 
documented the screening (yes/no), and if referral was made (yes/no). 
Finally, the screening questionnaire data collection form will document the 
patient responses to each question for completed questionnaires.  The collection form 
includes the subject ID number, forty columns that correspond to both the primary and 
conditional questions asked by the screening form, plus a final column that indicates 
whether this patient was referred or not. 
  In order to organize, sort and synthesize the answers provided by the patients, 
each response option has been numerically coded.  The codes for each question may be 
reviewed in the data collection form (See Appendix J).  The initial row of this form is 
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considered to be the master key for processing the data collected.  A separate index 
(Appendix K) has been created for the three questions on the form (13b, 14a and 15a) 
uniquely pertaining to the Rheumatoid Arthritis diagram, with fifty-five designated 
options denoting left, right and/or bilateral anatomical body locations. 
After the data has been compiled, the author, in collaboration with a statistician, 
will prepare the collected data for analysis.  Data collected from the chart review will be 
categorically analyzed using either the chi square or Fisher’s Exact test via SAS 9.4 
statistical software.  The chi square test is designed to provide marginal frequencies with 
information gathered from sources with two possible outcomes.  Should cells frequencies 
have expected values of less than 5, Fisher’s Exact test will be used to improve analytical 
accuracy. 
The data will be collated using a 2 x 2 table in which the two possible outcomes 
include whether the patient was screened/not screened by the provider, and whether a 
referral was made/not made to a specialist.  For this test, the alpha level of significance is 
0.05 (α = 0.05), and the degrees of freedom equals 1 (df = 1).  
The data collected from the patient questionnaire will be analyzed using Excel 
spreadsheet tools.  Descriptive statistics regarding the sample, as well as the prevalence 
(percentages) of symptoms relating to celiac disease, Crohn’s disease, and rheumatoid 
arthritis for these patients with psoriasis, will be calculated.   
3.9 Human Subjects 
Institutional Review Board (IRB) approval will be sought from the University of 
South Carolina as an exempt study for quality improvement.  Upon approval, this author 
will initiate project implementation, and be exclusively responsible for data collection 
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and management.  Three layers of protection will safeguard all data collected in order to 
ensure patient confidentiality.  All data collected during the creation of the coded 
identifier list, chart review data collection, and the screening questionnaire response 
collection will be migrated into three separate, encrypted and also password-protected 
excel files.  The files will then be stored on a password-protected laptop; the master 
coded identifier list will be stored separately from the collection forms data, on a second 
password-protected laptop.   
Data collection will occur throughout the lifespan of this quality improvement 
project, during the anticipated two-week project period, on a daily basis. The author alone 
will be responsible for chart reviews and data collection, which will occur in a private 
office on location at the clinic.  The author will retrieve completed patient charts from the 
discharge bin, and relocate to the reserved office area for chart review and data 
transcription.  Upon completion of chart review and data transcription, the author will 
return the charts to a newly designated bin, which will signal to staff that the chart is now 
ready for filing.  At no time will charts be left alone in the private office.   
Following data collection, but prior to data analysis, the identifier code list file 
will be destroyed via the free, downloadable Eraser software application (Eraser, 2016).  
Initiation of the Eraser program, a security tool for Windows platforms, will guarantee 
that the code list file has been permanently removed from the operating system.  Subject 
number alone will ultimately catalogue and ensure non-duplication of patient data; no 
patient data or responses will be linkable to patient identities.    
The data collected for this quality assurance project will focus solely on whether 
the provider screened the psoriatic patient, if the patient was referred for additional 
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specialty evaluation as a result, and the patients’ answers from the screening 
questionnaire.  The descriptive statistics produced from the questionnaire will reflect the 
cohort in the aggregate.   Finally, this project will practice patient respect throughout; 
patients have the right to refuse to participate in patient screening, no questions asked. 
3.10 Framework/model of research 
The Iowa model of evidence-based practice to promote quality care was very 
influential throughout the development of this practice-change project (Melnyk & 
Fineout-Overholt, 2011).  This model provides a step-by-step framework for nurse 
research utilization toward improving patient care.  The model’s first step was utilized to 
define an opportunity for improvement regarding knowledge about psoriasis and co-
autoimmunity with celiac disease, rheumatoid arthritis and Crohn’s disease.  The 
culmination of this step resulted in the PICO question.  The second and third steps in the 
Iowa model guided the evidence search and then, the critical appraisal of the literature 
included in this systematic review, ensuring the integrity and quality of the data collected.  
The fourth step directed the practice change design process through the identification of 
proposed practice change, identifying resources, evaluation design development and plan 
implementation (Melnyk & Fineout-Overholt, 2011).  The final two steps, five and six, 
influence the implementation of the pilot study and integration of study into standards of 
practice.  Step five outlines the critical steps for implementing the quality assurance 
project to include an evaluation of process, outcomes, costs and the development of 
conclusions and recommendations (Melnyk & Fineout-Overholt, 2011).  Step six of the 
model discusses how to integrate and maintain change in practice, through the process of 
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engaging stakeholders, incorporating the change into the practice, monitoring the process, 
and distribution of final outcomes (Melnyk & Fineout-Overholt, 2011). 
3.11 Strategies to reduce barriers and increase supports 
 To reduce potential barriers, such as provider or staff resistance to the 
implementation of a practice change, meetings with key change champion and opinion 
leader, MD One, and central staff players (PSRs) will be arranged.  MD One’s and staff 
buy-in is critical to the process of project implementation.  It is critical that MD One and 
staff appreciate the value of an increased understanding of their patient population toward 
promoting improved patient outcomes for patients with psoriasis.  At the meetings with 
MD One and staff, the need for change in practice, as well as the compelling evidence 
that supports this need for change, will be discussed.  Printed materials summarizing key 
points will supplement the discussion and be provided for distribution among clinic staff.    
Patient resistance to participate and complete the patient questionnaire is also a 
possible barrier.  The patient questionnaire has been designed to take no more than five 
minutes to complete, and will be provided to the patient with the other pre-appointment 
documentation.  The patient will be able to complete the questionnaire while waiting in 
the lobby, therefore, not extending the patient’s personal time burden at the visit.   
Finally, the author will be onsite for the duration of the project implementation 
and immediately available for patient questions, as well as staff and MD One support, in 
order to help ease the transition of a new practice change.   
3.12 Summary 
Additional population studies are urgently needed in order to determine the 
association of psoriasis with other AI disorders, and namely with celiac disease, Crohn’s 
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disease, and rheumatoid arthritis.  This quality improvement project will demonstrate that 
healthcare providers may have previously not been aware of co-autoimmunity in their 
psoriasis patients, demonstrate the ability to determine this information with a patient 
questionnaire, and foster increased awareness among healthcare providers about the 
autoimmune state of their psoriatic patients. 
Clinicians should consider psoriasis as a systemic inflammatory disorder with 
potential for other autoimmunity issues, rather than an isolated skin disease.  Increased 
awareness about co-autoimmunity in the patient with psoriasis is necessary for optimal 






The aim of this project was to assess the utility of early screening in patients with 
psoriasis in order to facilitate earlier diagnosis of CD, RA and CrD, which would 
consequently initiate earlier treatment and improve long-term patient outcomes.  The 
outcomes measured include the responses from the patient questionnaire and if the 
provider documented screening for polyautoimmunity and referral indications.  Chapter 
four provides a summary of these results from the quality improvement project and is 
divided into the following sections:  description of the sample, analysis of the research 
questions, and conclusion.   
The analysis is divided into four sub-sections.  The first sub-section focuses on 
the answers to the primary questions that directly fed the algorithms.  The second sub-
section discusses the answers to the conditional questions, which collected additional 
information on symptoms.  The third sub-section discusses the retrospective chart review, 
and the last sub-section examines more closely the patients who fulfilled the requirements 
for additional evaluation for celiac disease, Crohn’s disease and rheumatoid arthritis 
based on their reported symptoms.   
		 84	
4.2 Description of Sample 
 This quality improvement project occurred during the weeks of June 12, 2017 
through June 23, 2017, covering 10 business days at a Northern Virginia dermatology 
clinic.  A total of # (n=261) were seen at the clinic for a variety of different skin 
disorders.  Thirty-four adult patients with either a history of psoriasis or a new diagnosis 
of psoriasis completed the patient questionnaire during this timeframe, which assessed for 
the presence of evidence-based signs and symptoms for celiac disease, Crohn’s disease 
and rheumatoid arthritis.  Seventeen of these patients (50%) were female; seventeen 
(50%) were male.  The mean age of the psoriatic patients was 55.71 years old, ranging in 
ages 18 to 81 years old.   
4.3 Analysis of Research Questions  
Two unit of analysis were identified for this quality improvement project.  The 
first unit of analysis was the patient questionnaire. The second unit of analysis was the 
provider’s documentation of the patient questionnaire and subsequent referral, if 
indicated based on the questionnaire.  Six tables are presented below to review the data 
collected from this quality improvement project.   
Patient Questionnaire:  Primary Questions.  Table 4.1 depicts the participants’ 
responses to the seventeen primary questions from the patient questionnaire.  Frequency 
data indicated that the most reported symptom was a history of vitamin D deficiency 
(38.24%).  Thirty percent of psoriatic patients reported having a first-degree relative with 
celiac disease, Crohn’s disease or rheumatoid arthritis.  The next most frequently reported 
symptoms were for rheumatoid arthritis: daily joint or muscle pain > 6 weeks (29.41%), 
daily tender or swollen joints > 6 weeks (23.53%), and weakness or fatigue > 6 weeks 
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(23.53%).  The most reported GI symptom was abdominal distention and/or bloating after 
eating (14.71%).  The least reported symptoms, at 2.94% each, were abdominal pain after 
eating, painful bowel movements, and running a fever in the past 4 weeks (Table 4.1). 
Table 4.1 Patient Questionnaire Frequency Distributions / Primary Questions 
 
Question # Question Yes No 
  N % N % 
11 Has a HCP ever 
told you that you 
have a Vitamin 
D deficiency? 
13  38.24 21  61.76 
1 Do you have a 
1st degree 
relative with 




29.41 24  70.59 
14 Have you had 
joint or muscle 
pain on a daily 
basis for > 6 
weeks? 
10  29.41 24  70.59 
15 Have you had 
any tender or 
swollen joints on 
a daily basis for 
> 6 weeks? 
8  23.53 26  76.47 
17 Have you had 
weakness or 
fatigue for > 6 
weeks? 
8  23.53 26  76.47 
13 Have you had 
morning 
stiffness in any 
of your joints for 
> 60 minutes for 
> 6 weeks? 
6  17.65 
 
28  82.35 
16 Have you had 
tingling 
sensations in 
your hands or 
feet on a daily 
basis for > 6 
weeks? 
6  17.65 28  82.35 




5  14.71 29  85.29 
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Patient Questionnaire:  Frequency Distributions / Conditional Questions.   
Tables 4.2, 4.3 and 4.4 depict the responses for the nine conditional questions 
asked by the patient questionnaire.  If a patient answered “yes” to any of the nine 
conditional questions, they were then prompted to answer additional questions.  The 
additional questions were developed in order to collect supplementary information related 
to the patient’s initial positive response.  These responses are also presented by 
frequency. The primary questions are shaded in grey, by row, and the related conditional 
responses are indented just below, a summary of which follows. 
eating? 
7 Have you ever 
seen blood in 
your stool? 
5  14.71 29  85.29 
12 Has a HCP ever 
told you that you 
have elevated 
liver enzymes? 
4  11.76 30  88.24 
2 Do you have 
chronic or 
recurrent 
diarrhea (≥ 3 
loose stools per 
day for > 4 
weeks)? 
2  5.88 32  94.12 
3 Have you been 
losing weight? 
2  5.88 32  94.12 
9 Has a HCP ever 
told you that you 
have IBS? 
2  5.88 32  94.12 
10 Has a HCP ever 
told you that you 
were anemic? 
2  5.88 32  94.12 





2.94 33  97.06 
6 Is it painful to 
have a bowel 
movement? 
1  2.94 33  97.06 
8 Have you had a 
fever in the past 
4 weeks? 
1  2.94 33  97.06 
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For the 29.41% psoriatic patients that reported having a first-degree relative with 
CD, CrD or RA, 46.51% of individuals reported that this relative was their mother.  CD 
was reported in 38.46% of the cases, with CrD and RA each being reported in 30.76% of 
the cases of first-degree relative.  One individual had a mother with both CD and RA; a 
second individual reported having a child with both CD and CrD, and a third individual 
reported having a mother with CD and a brother with CrD. 
Joint and muscle pain for greater than six weeks was reported by 29.41% of 
psoriatic patients.  Tender and swollen joints on a daily basis for greater than six weeks 
was reported by 23.53%.  17.65% reported morning stiffness in their joints for more than 
60 minutes a day for greater than six weeks.  Although responses varied per patient, 
collectively these individuals indicated that their pain, tenderness, swelling and stiffness 
was located either bilaterally, or unilaterally, at the neck, shoulders, hands, fingers, hips, 
knees, ankles, and feet.  Sixty percent of these respondents indicated that their pain was 
between a 5-7 on a pain scale of 0 (no pain) to 10 (worst pain of their life).  50% reported 
a “constant” pain, and 40% described their pain as “aching.”  Fifty percent of the patients 
that indicated morning stiffness said that they experienced it everyday.   
Weakness or fatigue for greater than 6 weeks was reported in 23.53% of psoriatic 
patients, and 55.56% indicated that they experienced their weakness and fatigue 1-3 days 
per week.  Two patients (5.88%) reported weight loss over the past 6 months.  One 
individual reported a loss of 15-pounds and the other reported a 20-pound loss.  Only one 
patient (2.94%) reported abdominal pain after eating, in the LUQ, causing 3/10 cramping 
pain that lasted for one hour.  Finally, one patient (2.94%) reported having a fever of 
101°C in the past 4 weeks. 
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Table 4.2 Questionnaire Frequency Distributions / First Degree Relative 
 
 











1 Do you 





RA?   
  10 patients 
reported one or 
more 1st degree 
relative(s) with 
CD, CrD and/or 
RA. 
29.41 
  Do you have a 
mother/father/sister/ 








































  2 patients reported 
losing weight. 
5.88 
  How much weight have 














  1 patient reported 
abdominal pain 
2.94 
  Where does your pain 
occur? 
LUQ 1  100 
  How would you rate your 
pain? 
3/10 1  100 
  How long does the pain 
last? 
1 hour 1  100 
  How would you describe 
the pain? 
Cramping 1  100 
8 Have you 
had a 
fever in 
the past 4 
  1 patient reported 




Table 4.4  Questionnaire Frequency Distributions / Conditional Arthritis Symptoms 
 
weeks? 









Conditional Question / Response N % 
14 Have you 
had joint 
or muscle 





 10 patients 




  Where is your pain located? 
 
• bilateral knees 
• bilateral neck, bilateral shoulders, 
bilateral hips 
• bilateral neck, right shoulder, left knee, 
left ankle 
• bilateral pointer fingers, bilateral 
middle fingers, bilateral ring fingers, 
bilateral pinky fingers 
• left hand, left ankle, right foot 
• left hip, left knee 
• left shoulder, bilateral hands, bilateral 
hips, bilateral feet 
• left shoulder, left hand 
• left shoulder, left hip, left knee 





























































  How long does the pain 
last? 





































































 8 patients reported 
tender or swollen 
joints 
23.53 
  Which joints have been tender or 
swollen? 
 
• bilateral ankles 
• bilateral neck, bilateral shoulders 
• bilateral pointer fingers, bilateral 
middle fingers, bilateral ring fingers, 
bilateral pinky fingers 
• bilateral pointer fingers, bilateral 
middle fingers, bilateral ring fingers, 
bilateral pinky fingers, bilateral ankles, 
bilateral feet 
• right ankle, left foot 
• right knee 
• right pointer finger, right middle 







































for > 6 
weeks? 
  8 patients reported 
weakness/fatigue 
23.53 
  How often do you have 














13 Have you   6 patients reported 17.65 
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Chart Review.  Table 4.5 depicts the data collected during the chart review.  A 
total of 261 patient charts were reviewed.  For 227 of the charts, the review was 
completed and closed when the DNP project investigator determined that the patient did 
not have a history of, or a new diagnosis for, psoriasis. The remaining 34 patient charts 
demonstrated either a history of, or a new diagnosis for, psoriasis.  Provider 
documentation for all 34 patients demonstrated 100% compliance for noting that the 
patient a) had been screened, and b) if referral was or was not indicated.   









for > 6 
weeks? 
joint stiffness 
  How often do you have 
morning stiffness > 60 
minutes? 
Every day  
1-2 days/ 
wk  









  Which joints are stiff? 
 
• bilateral hands, left knee 
• bilateral neck, bilateral shoulders, 
bilateral hips 
• bilateral neck, bilateral shoulders, right 
wrist, bilateral pointer finger, bilateral 
middle fingers, bilateral ring fingers, 
bilateral pinky fingers, right hip, 
bilateral feet 
• bilateral pointer finger, bilateral 
middle finger, bilateral ring finger, 
bilateral pinky finger 
• left hand, left ankle, right foot 
• left pointer finger, left middle finger, 



































initially had intended on categorically analyzing the chart review data with a chi square 
test or Fisher’s Exact test.  The purpose of this analysis was to provide marginal 
frequencies with information gathered from sources with two possible outcomes.   Since 
100% compliance occurred, neither the chi square nor Fisher’s Exact test could be 
utilized.  On the recommendation of the collaborating statistician, no alternative tests 
were appropriate for further analyzing this data.   












(n) N N % N % N % 
261 34 34 100 34  100 34  100 
 
Referred Patient Symptoms.  Table 4.6 depicts the signs and symptoms for the 
eleven patients who were referred for additional evaluation based on their patient 
questionnaire responses.  Prior to discussing these results, a brief recap is provided first 
of the evidence-based algorithms for referral care.  CD should be considered in any 
patient with a first-degree relative with CD and who also demonstrates any of the targeted 
GI symptoms.  Without a first-degree relative, CD should be considered if the patient has 
three or more of the GI symptoms (See Appendix E).  CrD evaluation is indicated for 
patients who have a first-degree relative with CrD and who demonstrate any of the GI 
symptoms acknowledged to occur with CrD.  If the patient does not have a first-degree 
relative, they may be considered if they have had chronic diarrhea for more than 4 weeks 
and have at least one of the identified GI symptoms (See Appendix F).  Finally, patients 
should be considered for RA if they have synovitis in at least one joint or three or more 
arthralgia symptoms (See Appendix G). 
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As per the chart review, the responses provided by 11 of the 34 psoriatic patients 
indicated that they should receive additional evaluation by either a gastroenterologist or a 
rheumatologist.  Upon development of Table 4.6, however, the author realized that two of 
the patients (subjects 8 and 23) did not actually satisfy the algorithm requirements.  This 
indicates that an element of user-error compromised the process when evaluating the 
completed questionnaires. 
The remaining nine patients (26.47%) did, in fact, satisfy the algorithms.  Based 
on the patient questionnaire responses, five individuals fulfilled the requirements for 
additional celiac disease evaluation and six individuals fulfilled the requirements for 
additional rheumatoid arthritis evaluation. Two of the nine patients merited additional 
evaluation for both celiac disease and rheumatoid arthritis.  No patients were referred for 
possible Crohn’s disease.  In the table below, for each of the subjects a red “X” depicts 
the patient’s reported GI symptoms, while a blue “X” depicts reported arthritis 
symptoms. 
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11 M 4
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12 M 5
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          X    X   X 
46 M 6
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X      X           X 



























    
 
X X X  X X X  X X X  X X 
X 
GI Symptoms = X; arthritis symptoms =X 
4.4 Conclusion 
 This quality improvement project highlights several important facts. First, with 
proper planning, time commitment and a champion for change, real process 
modifications in health care management are possible.  By utilizing and implementing the 
steps provided by the Iowa Model for Evidence Based Practice, the foundation for change 
was established for successful screening of adult patients with psoriasis for celiac disease, 
Crohn’s disease, and rheumatoid arthritis.  Of the 34 patients identified with a diagnosis 
for psoriasis, all were appropriately screened for polyautoimmunity.  Provider 
documentation demonstrated buy-in and compliance with this project.   
Although two patients were inappropriately flagged for additional evaluation, this 
provides an opportunity to re-evaluate the patient questionnaire review step.  This DNP 
Project investigator theorizes that the responses to the conditional questions, whose 
answers are not applied against the algorithms, but were meant for collecting additional 
symptom history, may have complicated the questionnaire review.  With this in mind, 
three possible methods for improving this step have been identified.    
The simplest option would be to have a PSR pre-screen the questionnaire and 
indicate via highlighter marker only the positive answers to primary questions before 
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provider review. Further, an algorithm check-box could be developed and completed for 
each questionnaire.  This would provide an alternative and more concise view of 
responses as they relate to the algorithms.  Unfortunately, with both of these alternatives, 
an opportunity for human-error still exists.  The most sophisticated option includes the 
development of a computer-based questionnaire that would have built in rules for 
analyzing the data and automatically determining whether a referral is indicated.  
Obviously, this would require additional cost for software development and hardware 
(tablets or laptops for patient use), but would effectively eliminate user-error.    
The second significant take-away from this quality improvement project is that a 
real need exists for evaluating adult patients with psoriasis for polyautoimmunity and 
familial autoimmunity.  The fact that nine of the 34 patients, or 26.47% of psoriatic 
patients indicated for further evaluation based on their reported gastrointestinal and/or 
arthritic symptoms underscores that need for provider screening and is consistent with the 
literature.  Additionally, 29.41% of the psoriatic patients reported having a first-degree 
relative with CD, CrD and/or RA (8.82% of whom merited additional evaluation) 
supports the literature that states providers should be asking about their family history of 
autoimmune disorders.   
Despite having flagged nine patients with psoriasis for referrals, it is important to 
note that an indication for referral does not automatically indicate a diagnosis for co-
autoimmunity.  Additional evaluation is necessary in order to rule-out the many other 
possible differential diagnoses that could be associated with these symptoms.  The best-
case scenario as it relates to this quality improvement project is that these individuals 
with psoriasis may be identified as having celiac disease, Crohn’s disease or rheumatoid 
		 96	
arthritis earlier in the course of their disease, improving long-term patient outcomes.  
Worst-case scenario is that these patients are evaluated for these symptoms that need 
additional evaluation anyway. 
Despite this limitation, this quality improvement project demonstrates the 
merging of two relatively distinct evidence-based practices and research:  1) the current 
practice for evaluating patients for celiac disease, Crohn’s disease and rheumatoid 
arthritis and 2) the literature that suggests that these practices should be proactively 








The purpose of this project was to conduct a substantive review of the literature to 
determine if screening primary care patients with psoriasis will improve early detection 
of celiac disease, rheumatoid arthritis, and Crohn’s disease.		The aim of this project was 
to assess the utility of early screening in patients with psoriasis in order to facilitate 
earlier diagnosis of CD, RA and CrD, which would consequently initiate earlier treatment 
and improve long-term patient outcomes.  The evidence-based practice question is:  In 
adult patients aged 18 years and greater with psoriasis, does screening for celiac disease, 
rheumatoid arthritis, and crohn’s disease improve early detection for these autoimmune 
disorders?   A retrospective chart audit of 261 adult patients with psoriasis was conducted 
for polyautoimmunity screening.  Chapter five presents recommendations and 
implications for practice, education, research and policy development. 
5.2 Recommendations for Practice 
 According to the quality improvement project and consistent with the literature, 
there is evidence supporting prospective evaluation of adult patients with psoriasis for 
polyautoimmunity, specifically celiac disease, Crohn’s disease and rheumatoid arthritis.   
Findings from the project underscore the need for provider utilization of a patient 
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questionnaire that promotes identification of family history of autoimmune disorders, as 
well as significant symptoms for each of these three autoimmune disorders in the patient 
with psoriasis.   Further, the adoption of a screening process for polyautoimmunity in 
psoriatic patients in outpatient settings would help to narrow the provider’s focus on 
polyautoimmunity.  This is as opposed to managing symptoms without respect for the 
relationship among autoimmune diseases, missing the potential connection, and allowing 
AI disease to progress unchecked. 
5.3 Recommendations for Education 
 Improved clinical awareness among health care providers about the coexistence of 
AI diseases within individuals may also play a critical role in providing the best patient 
care and in achieving the best patient outcomes.  Health care practitioners must 
acknowledge that the presence of one AI disease may be indicative for the potential of 
other AI diseases.  Dermatologists and primary care providers in particular, as the usual 
gatekeepers for diagnosis and management of psoriasis, should been keenly aware of the 
possibility of other, latent AI disease in the adult patient with psoriasis.   
 Ideally, this improved awareness should start in the classroom.  The educational 
institution’s commitment to producing the best future health care providers should 
include foundational instruction regarding autoimmune disorders as a disease continuum 
worthy of its own category, and not simply as part of the current and traditional disease 
classification by organ system.   
 Educating providers about prospective evaluation of polyautoimmunity in patients 
with psoriasis must include discussions on the background and significance of the most 
current genetic and population-based studies that tie psoriasis, celiac disease, Crohn’s 
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disease and rheumatoid arthritis to each other.   Research publications continue to be the 
best method for reaching the most providers in the field. 
5.4 Recommendations for Research 
Additional research and improved awareness of autoimmune disorders, among 
both the public and healthcare providers, remains the cornerstone of future efforts to 
better understand autoimmune disorders, to better understand their co-existence, and 
toward a better plan for diagnosis and management of AI disorders.  Despite research 
advances made in the past two decades, substantial deficits remain in the understanding 
of psoriasis, the most commonly diagnosed AI disorder in the United States.   
Specifically, a greater understanding of the pathogenesis of psoriasis, comorbidities, and 
patient treatment demands further research in these areas.  However, psoriasis research 
should not be conducted within a vacuum.  While it is critical to understand how psoriasis 
stands alone as an autoimmune disorder, it is also imperative to develop research toward 
understanding how and why psoriasis co-exists with other autoimmune disorders.  For 
example, why is there a 2.3-fold greater risk of celiac disease co-occurring with psoriasis 
(Wu et al., 2013)?  And compared to individuals without psoriasis, why do subjects with 
psoriasis have a 3.02-fold increased risk of rheumatoid arthritis (Tsai et al., 2011)?  Aside 
from seeking answers to these questions about psoriasis and its co-existence with other 
AI disorders, there also exist other compelling reasons for targeting psoriasis in 
autoimmune research.   
First, psoriasis is known to be the most prevalent AI disorder in the United States, 
affecting as many as 7.5 million Americans, and 125 million worldwide (National 
Psoriasis Foundation, 2014).  Second, the concept of pan autoimmunity, or diathesis of 
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autoimmunity (Ali & Warren, 2013; Pender et al., 2002), proposes that individuals with 
one autoimmune disease are predisposed genetically to other autoimmune diseases.  
Extrapolating the pan autoimmunity theorem to apply to patients with psoriasis, we can 
therefore expect that these individuals would also be genetically predisposed to other 
autoimmune diseases.  However, this supposition is not just a leap of blind faith; 
epidemiological data already supports this hypothesis.  The literature reviewed for this 
project strongly suggests a link between psoriasis and celiac disease, rheumatoid arthritis 
and Crohn’s disease (Augustin et al., 2010; Bhatia et al., 2014; Birkenfeld et al., 2009; 
Cohen et al., 2009; Damasiewicz-Bodzek & Wielkoszynski, 2008; Einarsdottir et al., 
2009; Li et al., 2013; Makredes et al., 2009; Qui et al., 2013; Radtke et al., 2015; Tsai et 
al., 2011; Tsoi et al., 2013; Wolf et al., 2008; Wu et al., 2012). 
Therefore, given the sheer number of individuals available for basing research 
inquiries, plus the existing data suggesting AI co-existence patterns, individuals with 
psoriasis would seem to be a highly relevant patient population by which to start building 
on our current understanding of polyautoimmunity.  The research community must, 
therefore, pay greater attention to the underlying genetic relationships between psoriasis 
and other autoimmune disease, and to how this genetic relationship influences the 
individual and familial clustering of many inflammatory and metabolic disease processes.   
Another challenge to the field of immunology that demands attention is the 
development of reproducible, cost-efficient, and sensitive tools for early and definitive 
diagnosis, disease staging, and identification of at-risk individuals (NIH, 2005).  
Fortunately, many research initiatives are currently underway and increased NIH research 
funding for autoimmune diseases has trended upward from $587 million in 2007 to $821 
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million in 2013 (AARDA, 2011).  And in 2009, the Centers for Disease Control and 
Prevention (CDC) led an effort to develop the first-ever public health agenda for psoriasis 
and psoriatic arthritis, which will guide future public health efforts and research into 
these diseases.  Congress approved $1.5 million to the CDC to begin the first federal 
effort to collect data on people with psoriatic diseases (CDC, 2010). 
Among the many initiatives currently in place are the Multiple Autoimmune 
Diseases Genetics Consortium (MADGC), Environment/Infection/Gene Interactions in 
Autoimmune Diseases, Autoimmunity Centers of Excellence, Autoimmune Biomarkers 
Collaborative Network, Cooperative Study Group for Autoimmune Diseases Prevention 
(Prevention Centers), Autoimmunity Centers of Excellence, and Clinical Trials and 
Clinical Markers in Immunologic Diseases (AARDA, 2011).  Each of these initiatives’ 
overall objective, while unique, is to facilitate autoimmunity research collaboration, to 
identify and characterize the genes that are common to these diseases, to develop biologic 
markers for measuring disease activity, risk, and therapeutic effect, and to advance our 
understanding of treatment interventions (AARDA, 2011).   
5.5 Recommendations for Policy 
 The challenges, and solutions, to the autoimmune problem are wide-ranging and 
complex.  As the work continues in solving the autoimmunity puzzle, the immediate need 
is for increased awareness among patients and healthcare providers about the immensity 
of this public health concern and for Congress to recognize autoimmunity’s overall 
financial burden to the nation.  The challenges of autoimmunity need to be recognized as 
a high priority agenda item today. 
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5.6 Limitations 
This quality improvement project capitalizes on the most current research and 
evidence-based literature, however, there are many limitations to this project that must be 
acknowledged.  A prominent limitation of this project is that the patient questionnaire and 
algorithms’ ability to adequately assist with the identification of celiac disease, Crohn’s 
disease and rheumatoid arthritis have not been investigated; neither the questionnaire, nor 
the algorithms have been tested for reliability or validity.  Fortunately, it was never 
intended for this questionnaire to be a replacement for additional medical history, 
physical exam, or testing.  The objective was to assist the provider in identifying potential 
signs and symptoms for other AI disease in an at risk patient population, adult patients 
with psoriasis.   
Other limitations include location, sample size, and length of study. While a 
dermatology clinic lends itself perfectly to this quality improvement project in terms of 
patient population, a limitation is that the patient must then be referred out for additional 
evaluation, if suspicion is high for other disease. The dermatologist in this case, and most 
likely in other dermatology clinics, will not be willing to conduct further studies prior to 
the specialty referral.  While this is considered to be a disadvantage in the dermatology 
clinic, it would actually be an advantage in the primary care practice setting. Additional 
testing could be conducted in the primary care setting before deciding if specialty referral 
was merited.   
Finally, the sample size for this quality improvement project was relatively small 
(n = 34) and all patient participants were from an urban part of the state of Virginia.  The 
length of time for the project was a significant limitation to this study, allotting for only 
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two weeks to implement the patient questionnaire.  Due to the short lifespan of the 
project, the author does not know the result of any of the patient referrals. 
5.7 Conclusion 
While many of the AI diseases have low prevalence as a single occurring health 
disease, collectively autoimmune diseases are the third most common category of disease 
in the United States after cancer and heart disease (NIH, 2005) affecting approximately 5-
8% of the population or approximately 23.5 million Americans.   Psoriasis is known to be 
the most prevalent AI disease in humans (Raychaudhuri, 2014), affecting approximately 
2-5% of the world population and as many as 7.5 million Americans (NIH, 2005).  The 
concept of pan autoimmunity, or diathesis of autoimmunity (Ali & Warren, 2013; Pender 
et al., 2002), proposes that individuals with one autoimmune disease are predisposed 
genetically to other autoimmune diseases.  Finally, the literature suggests that there is a 
genetic link between psoriasis, celiac disease, Crohn’s disease and rheumatoid arthritis 
(Augustin et al., 2010; Bhatia et al., 2014; Birkenfeld et al., 2009; Cohen et al., 2009; 
Damasiewicz-Bodzek & Wielkoszynski, 2008; Einarsdottir et al., 2009; Li et al., 2013; 
Makredes et al., 2009; Qui et al., 2013; Radtke et al., 2015; Tsai et al., 2011; Tsoi et al., 
2013; Wolf et al., 2008; Wu et al., 2012). 
In light of these statistics, as providers, researchers, educators and policy makers, 
we must recognize the two following realities: 1) the significance of familial 
autoimmunity and polyautoimmunity to the adult patient with psoriasis, and 2) the 
possibility of encountering many undiagnosed and subclinical cases of “other” 
autoimmune disease in the psoriatic patient population.  By acknowledging these 
autoimmune principles, the provider is able to then act proactively for the patient and 
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routinely consider the possibility that a patient with psoriasis may develop celiac disease, 
Crohn’s disease or rheumatoid arthritis over the course of their lifetime.  Providers are 
able to have a lasting impact on the well-being of psoriatic patients through the 
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from guinea pig 
liver (a-GP-tTG) for 




IgG (p < 0.001, 
p=0.000001, and 
p=0.01) than do 
patients without 
psoriasis.   
Furthermore, in 46% 
of the cases for IgG, 
and as much as 66% 
of the IgA cases, 
titres of antibodies 
were higher than the 
90th percentile of the 
control values.   
Patients with 
psoriasis also had 
higher mean levels 
of IgA antibodies 










< 0.001, P = 0.036 
and p=0.002); 54% 
of the cases were 
higher than the 90th 
percentile of the 
control values.  The 
titres of antibodies 
against gliadin 
between psoriatics 
and controls were 
increased at 
statistically 
significant levels for 
IgA (p < 0.001, p = 
0.000000 and p = 
0.0005), but not for 
IgG (p > 0.01, p = 
0.75, and p = 0.244).   
And no anti-
endomysial 
antibodies for IgA 
were found in any 
serum, either cases 





of a-GP-tTG IgA, a 
GP-tTg IgG and 
AGA IgA.  
Concentrations of a-
h-r-tTG IgA, a-GP-
tTG IgA and AGA 
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Fifty-one of the 255 
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lod score of 0.83 
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despite the low 
score, an association 
of IL23R with 
psoriasis was 
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(> 3 bowel 
movements per 
day and > 4 
weeks) and ≥ 1 
of the following  
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–  Abdominal 
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37.8 °C during 
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Appendix C 
Scottish Intercollegiate Guidelines Network (SIGN) Grading System 1999 – 2012: 
Grades of Recommendations 
 
A At least one meta-analysis, systematic review, or RCT rated as 1++, and directly 
applicable to the target population; or 
 
A body of evidence consisting principally of studies rated as 1+, directly applicable 
to the target population, and demonstrating overall consistency of results 
 
B A body of evidence including studies rated as 2++, directly applicable to the target 
population, and demonstrating overall consistency of results; or 
 
Extrapolated evidence from studies rated as 1++ or 1+ 
 
C A body of evidence including studies rated as 2+, directly applicable to the target 
population and demonstrating overall consistency of results; or 
 
Extrapolated evidence from studies rated as 2++ 
 
D Evidence level 3 or 4; or 
 






















1) Do you have a first-degree relative with celiac disease, Crohn’s disease or rheumatoid 
arthritis? 
o No 
o Yes  
 
 If you answered yes to the question above, please complete the following: 
 My mother / father / sister / brother / child has: 
o Celiac disease 
o Crohn’s disease 
o Rheumatoid arthritis 
   
2) Do you have chronic or recurrent diarrhea?  (≥ 3 loose stools per day for > 4 weeks) 
(CD/CrD) 
o No 
o Yes  
 
 
3) Have you been losing weight? (CD/CrD) 
o No 
o Yes  
 
 If yes, how much weight have you lost over the past 6 months?  ___________ 
  
 
4) Do you have abdominal pain after eating? (CD/CrD) 
o No 
o Yes  
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If yes, indicate on the diagram below where your pain occurs: 
 
 
 How would you rate your pain? 
 
 0 1 2 3 4 5 6 7 8 9 10 
none mild moderate very bad unbearable 
 
 
How long does the pain last?  __________________ 
 











o other: _____________ 
 
5) Do you suffer from abdominal distention and/or bloating after eating? (CD) 
o No 
o Yes  
 
6) Is it painful to have a bowel movement? (CrD) 
o No 
o Yes  
 
7) Have you ever seen blood in your stool? (CrD) 
o No 
o Yes  
 
8) Have you had a fever in the past 4 weeks?  (CrD) 
o No 
o Yes  
 




9) Has a health care provider ever told you that you have irritable bowel syndrome? 
(CD/CrD) 
o No 
o Yes  
 
10) Has a health care provider ever told you that you were anemic? (CD/CrD) 
o No 
o Yes  
 
11) Has a health care provider ever told you that have a vitamin D deficiency? (CD/CrD) 
o No 
o Yes  
 
12) Has a health care provider ever told you that you have elevated liver enzymes?   
(CD/CrD) 
o No 
o Yes  
 
13) Have you had morning stiffness in any of your joints for > 30 minutes for > 6 weeks?  
(RA) 
o No 
o Yes  
 
 If yes, how often do you have morning stiffness > 30 minutes? 
o every day 
o 1-3 days a week 
o 4-6 days a week 
 









14) Have you had joint or muscle pain on a daily basis for > 6 weeks? (RA) 
o No 
o Yes  
 





How would you rate your pain? 
 
 0 1 2 3 4 5 6 7 8 9 10 






How long does the pain last?  __________________ 
 










o other: _____________ 
 
15) Have you had any tender or swollen joints on a daily basis for > 6 weeks?  (RA) 
o No 
o Yes  
 




16) Have you had tingling sensations in your hands or feet on a daily basis for > 6 
weeks? (CD/RA) 
o No 
o Yes  
 
17) Have you had weakness or fatigue for > 6 weeks? (RA) 
o No 
o Yes  
 
 If yes, how often do you have weakness or fatigue? 
o every day 
o 1-3 days a week 




Referral Algorithm for Celiac Disease 
 
Patient has a 1st degree relative with Celiac disease? 
Yes No 
Refer if patient presents with any of the 
following: - ≥ 3 loose stools per day for > 4 
weeks - Abdominal pain after eating - Abdominal distention/bloating after 
eating - Weight loss - Has ever been told they have IBS - Hx of malabsorption problems 
(anemia, vitamin D deficiency) - Hx of elevated liver enzymes 
 
Refer if patient presents with ≥ 3 of the 
following: - ≥ 3 loose stools per day for > 4 
weeks - Abdominal pain after eating - Abdominal distention/bloating after 
eating - Weight loss - Has ever been told they have IBS - Hx of malabsorption problems 





Referral Algorithm for Crohn’s Disease 
 
Patient has a 1st degree relative with Crohn’s disease? 
Yes No 
Refer if patient presents with any of the 
following: - ≥3 loose stools per day for > 4 
weeks - Abdominal pain after eating - Weight loss - Painful defecation - Blood in stool - Has ever been told they have IBS - Hx of malabsorption problems 
(anemia, vitamin D deficiency) - Hx of elevated liver enzymes 
 
Refer if patient presents with ≥ 3 loose 
stools per day for > 4 weeks AND ≥ 1 of 
the following symptoms: - Abdominal pain after eating - Weight loss - Painful defecation - Blood in stool - Fever in the last 4 weeks - Has ever been told they have IBS - Hx of malabsorption problems 





Referral Algorithm for Rheumatoid Arthritis 
 










Coded Identifier List 
 
Patient Name Chart Number Visit Date Subject Number 
	 	 	 	
	 	 	 	
	 	 	 	
	 	 	 	
	 	 	 	
	 	 	 	
	 	 	 	
	 	 	 	
	 	 	 	
	 	 	 	
	 	 	 	
	 	 	 	
	 	 	 	
	 	 	 	
	 	 	 	
	 	 	 	
	 	 	 	
	 	 	 	
	 	 	 	
	 	 	 	
	 	 	 	
	 	 	 	
	 	 	 	
	 	 	 	
	 	 	 	
	 	 	 	
	 	 	 	
	 	 	 	
	 	 	 	




Chart Review – Data Collection Form 
 





1,2,3…	 No=0              
Yes=1 
No=0              
Yes=1	
No=0            
Yes=1	
No referral=0                         
Yes referral=1	
	 	 	 	 	
	 	 	 	 	
	 	 	 	 	
	 	 	 	 	
	 	 	 	 	
	 	 	 	 	
	 	 	 	 	
	 	 	 	 	
	 	 	 	 	
	 	 	 	 	
	 	 	 	 	
	 	 	 	 	
	 	 	 	 	
	 	 	 	 	
	 	 	 	 	
	 	 	 	 	
	 	 	 	 	
	 	 	 	 	
	 	 	 	 	
	 	 	 	 	
	 	 	 	 	
	 	 	 	 	
	 	 	 	 	
	 	 	 	 	
	 	 	 	 	
	 	 	 	 	




Screening Questionnaire – Data Collection Form 
(Excel columns shown below in vertical format) 
 
Subject # Visit Date 
Visit 
Time Age (years) Gender 1 
1,2,3… mm/dd/yyyy 0:00 # male=0 
female=1 
No=0              
Yes=1 
if yes - 1a if yes - 1b 2 3 
if yes - 3a 
(lbs) 4 
mother=0                                
father=1                                  
sister=2                               
brother=3                              
child=4 
CD=0              
CrD=1              
RA=2 
No=0            
Yes=1 
No=0              
Yes=1 
# No=0        
Yes=1 
if yes - 4a if yes - 4b if yes - 
4c (hrs) 
if yes - 4d if "other" 
- 4e 
5 
RUQ=0                                       
LUQ=1                                        























 No=0          
Yes=1 
6 7 8 if yes - 8a (°F) 9 10 
No=0                                         
Yes=1 
No=0           
Yes=1 
No=0           
Yes=1 
# No=0          
Yes=1 
No=0       
Yes=1 
11 12 13 if yes - 13a 
if yes - 
13b 14 
No=0                                         
Yes=1 
No=0           
Yes=1 
No=0          
Yes=1 
every day=0          





No=0          
Yes=1 
if yes - 14a if yes - 14b if yes - 
14c 
(hrs) 



























No=0          
Yes=1 
if yes - 15a 16 17 If yes - 17a if yes - 
15a 
Referred? 
See Appendix K No=0              
Yes=1 




































pointer finger (right)=19 
middle finger (right)=20 
ring finger (right)=21 
pinky finger (right)=22 
thumb (left)=23 
pointer (left)=24 
middle finger (left)=25 
ring finger (left)=26 
pinky finger (left)=27 
thumb (bilateral)=28 
pointer (bilateral)=29 
middle finger (bilateral)=30 
ring finger (bilateral)=31 










great toe (right)=41 
second toe(right)=42 
third toe (right)=43 
fourth toe (right)=44 
fifth toe (right)=45 
great toe (left)=46 
second toe (left)=47 
third toe (left)=48 
fourth toe (left)=49 
fifth toe (left)=50 
great toe (bilateral)=51 
second toe (bilateral)=52 
third toe (bilateral)=53 
fourth toe (bilateral)=54 




IRB  Approval 
 
NOT HUMAN SUBJECT RESEARCH 
 
ID:    Pro00066977 
Title:    Not Human Subjects Research 
PI:    Susan Ashbaugh 
Study Title:   Best Practice for Screening Adult Patients with Psoriasis for 
Polyautoimmunity: Celiac Disease, Rheumatoid Arthritis and Crohn's 
Disease 
Description:   A study application has been confirmed to be not human subject 
research. To navigate to the project workspace, click on the above ID. 
 
